// SURGERY Questions
// Auto-generated from questions.ts
// Total Questions: 67

import { Question } from '../types';

export const questions: Question[] = [
{
    id: "neet-pg-2024-4",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Vitamin to be supplemented after gastrectomy?",
    options: [
      "Vitamin A",
      "Vitamin C",
      "Vitamin B12",
      "Vitamin D"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Vitamin B12 (Option C)**\n\nüî¨ DETAILED EXPLANATION:\n\nAfter **gastrectomy**, **Vitamin B12 supplementation** is **MANDATORY and LIFELONG** due to loss of **intrinsic factor (IF)** production.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå NORMAL B12 ABSORPTION:\n\n**1. DIETARY B12 (Cobalamin)**\n   ‚Üí Found in meat, fish, dairy, eggs\n\n**2. STOMACH** üéØ\n   ‚Üí **Gastric acid** releases B12 from proteins\n   ‚Üí **Parietal cells** secrete **Intrinsic Factor (IF)** ‚≠ê‚≠ê‚≠ê\n   ‚Üí **IF binds to B12** forming **B12-IF complex**\n\n**3. DUODENUM & JEJUNUM**\n   ‚Üí B12-IF complex remains stable\n\n**4. TERMINAL ILEUM**\n   ‚Üí **Cubam receptors** bind B12-IF complex\n   ‚Üí B12 absorbed into blood\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö†Ô∏è POST-GASTRECTOMY:\n\n**NO STOMACH** ‚Üí ‚ùå **No Parietal Cells**\n\n   ‚Üì\n\n‚ùå **No Intrinsic Factor**\n\n   ‚Üì\n\n‚ùå **No B12 Absorption** (terminal ileum needs B12-IF complex)\n\n   ‚Üì\n\n**MEGALOBLASTIC ANEMIA** (develops in 2-5 years)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä POST-GASTRECTOMY DEFICIENCIES:\n\n**‚òÖ‚òÖ‚òÖ VITAMIN B12** ‚≠ê‚≠ê‚≠ê **(MOST IMPORTANT)**\n\n‚Ä¢ **Mechanism:** No intrinsic factor\n‚Ä¢ **Time:** 2-5 years (after stores deplete)\n‚Ä¢ **Consequences:**\n  ‚Üí **Megaloblastic anemia** (macrocytic)\n  ‚Üí **Neurological:** Subacute combined degeneration\n  ‚Üí **Peripheral neuropathy**\n  ‚Üí **Cognitive impairment**\n‚Ä¢ **Treatment:** **IM B12** 1000 Œºg monthly (lifelong) ‚≠ê\n\n**‚òÖ‚òÖ IRON**\n‚Ä¢ **Mechanism:** ‚Üì Gastric acid, rapid emptying\n‚Ä¢ **Result:** Microcytic anemia\n\n**‚òÖ FOLATE**\n‚Ä¢ Decreased intake\n\n**‚òÖ CALCIUM & VITAMIN D**\n‚Ä¢ Malabsorption ‚Üí Osteoporosis\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ WHY OTHER OPTIONS WRONG:\n\n‚ùå **Vitamin A:** Not specifically affected, liver stores last years\n\n‚ùå **Vitamin C:** Absorbed throughout small intestine, doesn't need stomach\n\n‚ùå **Vitamin D:** While ‚Üì absorption occurs, **B12 is MORE CRITICAL and INEVITABLE**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**POST-GASTRECTOMY = LIFELONG B12 MANDATORY** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**No Stomach, No IF, No B12** ‚Üí Must give **B12 shots forever!**\"\n\n‚Ä¢ **Parietal cells** (stomach) produce **IF**\n‚Ä¢ **IF essential** for B12 absorption in **terminal ileum**\n‚Ä¢ Start supplementation **immediately** (don't wait!)",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-8",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Renal mass, haematuria, flank pain:",
    options: [
      "Clear cell",
      "Papillary",
      "Chromophobic",
      "Belini"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Chromophobe RCC (Option C)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Renal Cell Carcinoma (RCC)** presenting with the **CLASSIC TRIAD** (renal mass + hematuria + flank pain) can be of various subtypes. **Chromophobe RCC** is associated with the **BEST PROGNOSIS** among all RCC subtypes, making it the correct answer for favorable outcomes.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå RCC SUBTYPES COMPARISON:\n\n**1. CLEAR CELL RCC** (70-80%) ‚ùå\n\n‚Ä¢ **MOST COMMON** subtype ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Origin:** Proximal convoluted tubule\n‚Ä¢ **Genetics:** **VHL gene** mutation (3p deletion) on chromosome 3\n‚Ä¢ **Histology:**\n  ‚Üí Clear cytoplasm (glycogen, lipid)\n  ‚Üí Delicate vascular network\n  ‚Üí \"Chicken-wire\" capillaries\n‚Ä¢ **Prognosis:** **Intermediate** (worse than chromophobe)\n‚Ä¢ **Metastasis:** Bone, lung, liver, brain\n‚Ä¢ **Associated with:** Von Hippel-Lindau syndrome\n\n**2. PAPILLARY RCC** (10-15%) ‚ùå\n\n‚Ä¢ **2nd most common** subtype\n‚Ä¢ **Origin:** Proximal tubule\n‚Ä¢ **Genetics:** MET proto-oncogene, FH (fumarate hydratase)\n‚Ä¢ **Histology:**\n  ‚Üí Papillary/tubular architecture\n  ‚Üí Foamy macrophages\n  ‚Üí Psammoma bodies (Type 1)\n‚Ä¢ **2 Types:**\n  ‚Üí **Type 1:** Low grade, **BEST prognosis** within papillary\n  ‚Üí **Type 2:** High grade, **worse prognosis**\n‚Ä¢ **Prognosis:** **Better** than clear cell (but not as good as chromophobe)\n‚Ä¢ **Often bilateral** and multifocal\n\n**3. ‚òÖ CHROMOPHOBE RCC** ‚≠ê‚≠ê‚≠ê **(ANSWER - 5% of RCC)**\n\n‚Ä¢ **Origin:** Cortical collecting duct (intercalated cells)\n‚Ä¢ **Genetics:** **Multiple chromosome losses** (1, 2, 6, 10, 13, 17, 21)\n‚Ä¢ **Histology:**\n  ‚Üí **Large pale cells** with abundant cytoplasm\n  ‚Üí **\"Plant-like\" cell borders** ‚≠ê (distinct cell membranes)\n  ‚Üí **Perinuclear halo** (wrinkled raisinoid nuclei)\n  ‚Üí **Binucleation** common\n‚Ä¢ **Special stains:**\n  ‚Üí **Hale's colloidal iron (+)** ‚≠ê‚≠ê‚≠ê (diagnostic!)\n  ‚Üí **CD117 (c-KIT) positive**\n  ‚Üí CK7 diffusely positive\n‚Ä¢ **Prognosis:** **BEST prognosis** of all RCC subtypes! ‚≠ê‚≠ê‚≠ê\n  ‚Üí **5-year survival: 80-90%**\n  ‚Üí **Rarely metastasizes**\n  ‚Üí **Indolent behavior**\n‚Ä¢ **DDx:** Renal oncocytoma (benign, similar Hale's stain)\n\n**4. COLLECTING DUCT (BELLINI) RCC** (1-2%) ‚ùå\n\n‚Ä¢ **RAREST** and **MOST AGGRESSIVE** subtype ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è\n‚Ä¢ **Origin:** Medullary collecting ducts\n‚Ä¢ **Histology:**\n  ‚Üí Tubular/glandular pattern\n  ‚Üí Desmoplastic stroma\n  ‚Üí High-grade cytology\n‚Ä¢ **Location:** **Medullary** (vs others: cortical)\n‚Ä¢ **Prognosis:** **WORST** among all RCC subtypes ‚ö†Ô∏è\n  ‚Üí Often **metastatic at presentation**\n  ‚Üí Very aggressive\n  ‚Üí **5-year survival: <10%**\n‚Ä¢ **Association:** **Sickle cell trait** (medullary carcinoma variant)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLASSIC RCC TRIAD:\n\n**1. FLANK PAIN** (40% of patients)\n‚Ä¢ Dull, constant ache\n‚Ä¢ Due to mass effect/bleeding\n\n**2. HEMATURIA** (40-60% of patients)\n‚Ä¢ Gross or microscopic\n‚Ä¢ **Painless** hematuria\n‚Ä¢ Intermittent\n\n**3. PALPABLE ABDOMINAL/FLANK MASS** (25-45%)\n‚Ä¢ Indicates large tumor\n‚Ä¢ Late sign\n\n**IMPORTANT:** Only **10-15%** of patients present with **ALL 3 together**! ‚ö†Ô∏è\n\nMost patients are **asymptomatic** and diagnosed **incidentally** on imaging (\"incidentaloma\").\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö° OTHER CLINICAL FEATURES:\n\n**SYSTEMIC SYMPTOMS:**\n‚Ä¢ **Weight loss**\n‚Ä¢ **Fever** (20%)\n‚Ä¢ **Night sweats**\n‚Ä¢ **Fatigue, anemia**\n‚Ä¢ **Varicocele** (especially left-sided, acute onset - due to renal vein invasion)\n\n**PARANEOPLASTIC SYNDROMES (30%):**\n\n‚Ä¢ **Polycythemia** (5%)\n  ‚Üí **Erythropoietin (EPO) ‚Üë** production\n  ‚Üí Elevated hematocrit\n\n‚Ä¢ **Hypercalcemia** (10-20%)\n  ‚Üí **PTHrP** (parathyroid hormone-related peptide) secretion\n  ‚Üí Bone resorption\n\n‚Ä¢ **Hypertension**\n  ‚Üí **Renin ‚Üë** secretion\n  ‚Üí AV fistulas in tumor\n\n‚Ä¢ **Stauffer Syndrome**\n  ‚Üí **Non-metastatic hepatic dysfunction**\n  ‚Üí ‚Üë Alkaline phosphatase, ‚Üë transaminases\n  ‚Üí Hepatomegaly\n  ‚Üí Resolves after nephrectomy\n\n‚Ä¢ **Cushing syndrome**\n  ‚Üí **ACTH** secretion (rare)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç DIAGNOSIS:\n\n**IMAGING:**\n\n‚Ä¢ **CT abdomen with IV contrast** ‚≠ê (Gold standard)\n  ‚Üí **Heterogeneous enhancing mass**\n  ‚Üí Renal vein/IVC involvement?\n  ‚Üí Staging (T, N, M)\n\n‚Ä¢ **MRI** (if contrast allergy, better for IVC thrombus)\n\n‚Ä¢ **Ultrasound** (initial, often incidental finding)\n  ‚Üí Solid vs cystic\n\n**BIOPSY:**\n‚Ä¢ **Usually NOT needed** if imaging typical\n‚Ä¢ Reserved for:\n  ‚Üí Uncertain diagnosis\n  ‚Üí Small masses (<4 cm)\n  ‚Üí Metastatic disease (to confirm histology)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä STAGING & TREATMENT:\n\n**TNM STAGING:**\n‚Ä¢ **T1:** ‚â§7 cm, confined to kidney\n  ‚Üí T1a: ‚â§4 cm\n  ‚Üí T1b: 4-7 cm\n‚Ä¢ **T2:** >7 cm, confined to kidney\n‚Ä¢ **T3:** Extension into major veins or perinephric tissue\n‚Ä¢ **T4:** Beyond Gerota's fascia\n\n**TREATMENT:**\n\n‚Ä¢ **Localized disease:** **Radical nephrectomy** or **partial nephrectomy** ‚≠ê\n‚Ä¢ **Metastatic disease:**\n  ‚Üí **Targeted therapy:** Sunitinib, pazopanib (VEGF inhibitors)\n  ‚Üí **Immunotherapy:** Nivolumab, pembrolizumab (PD-1 inhibitors)\n  ‚Üí **mTOR inhibitors:** Everolimus, temsirolimus\n‚Ä¢ **RCC is resistant to chemotherapy and radiation!** ‚ö†Ô∏è\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìä PROGNOSIS RANKING (Best ‚Üí Worst):\n\n**1. Chromophobe RCC** ‚≠ê‚≠ê‚≠ê **(BEST - 80-90% 5-yr survival)**\n**2. Papillary RCC Type 1** (Good - 75-85%)\n**3. Clear Cell RCC** (Intermediate - 55-70%)\n**4. Papillary RCC Type 2** (Poor - 40-50%)\n**5. Collecting Duct/Bellini** ‚ö†Ô∏è **(WORST - <10%)**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**CHROMOPHOBE RCC = BEST PROGNOSIS** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"Chromophobe = CHROME = Shiny BEST prognosis!\"**\n\n‚Ä¢ **Chromophobe:** 5%, **BEST prognosis** (80-90% 5-yr survival)\n‚Ä¢ **Hale's colloidal iron (+)** = diagnostic for chromophobe\n‚Ä¢ **\"Plant-like\" cell borders** = chromophobe\n‚Ä¢ **Clear cell:** MOST common (70-80%), VHL gene\n‚Ä¢ **Collecting duct (Bellini):** WORST prognosis (<10%)\n‚Ä¢ **Classic RCC triad:** Mass + Hematuria + Flank pain (only 10% have all 3!)\n‚Ä¢ **Paraneoplastic:** Polycythemia (EPO), Hypercalcemia (PTHrP)\n‚Ä¢ **Treatment:** Surgery for localized; targeted/immuno for metastatic",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-12",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Child presents with sunlight causing eruptions, diagnosed with a DNA repair\ndefect. Which defect could it be?",
    options: [
      "Nucleotide excision",
      "Base excision repair",
      "Mismatch repair defect",
      "Recombination defect"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Nucleotide Excision Repair (NER) defect (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Xeroderma Pigmentosum (XP)** is a **rare autosomal recessive** disorder caused by defective **Nucleotide Excision Repair (NER)**. Patients cannot repair **UV-induced DNA damage**, leading to **extreme photosensitivity** and **1000x increased risk** of skin cancers. They are called **\"Children of the Night\"** because they must avoid sunlight.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå DNA REPAIR MECHANISMS:\n\n**‚òÖ NUCLEOTIDE EXCISION REPAIR (NER)** ‚≠ê‚≠ê‚≠ê **(ANSWER!)**\n\n‚Ä¢ **Repairs:** **UV-induced damage** (pyrimidine dimers), bulky DNA lesions\n‚Ä¢ **Defect causes:** **Xeroderma Pigmentosum (XP)** ‚≠ê\n‚Ä¢ **Mechanism:**\n  ‚Üí Recognizes **bulky DNA adducts** (thymine dimers from UV)\n  ‚Üí Excises **20-30 nucleotides** around damage\n  ‚Üí DNA polymerase fills the gap\n  ‚Üí Ligase seals the nick\n‚Ä¢ **Genes involved:** XPA-XPG (7 complementation groups)\n‚Ä¢ **Key feature:** Repairs **UV damage specifically**\n\n**‚Ä¢ BASE EXCISION REPAIR (BER)** ‚ùå\n\n‚Ä¢ **Repairs:** **Oxidative damage**, deamination, alkylation\n‚Ä¢ **Removes:** **Single damaged base** (not bulky lesions)\n‚Ä¢ **Enzyme:** DNA glycosylase\n‚Ä¢ **Defect causes:** MYH-associated polyposis (MAP)\n‚Ä¢ **Does NOT repair UV damage**\n\n**‚Ä¢ MISMATCH REPAIR (MMR)** ‚ùå\n\n‚Ä¢ **Repairs:** **Replication errors** (base-base mismatches)\n‚Ä¢ **Corrects:** Wrong nucleotide insertion during DNA replication\n‚Ä¢ **Genes:** MLH1, MSH2, MSH6, PMS2\n‚Ä¢ **Defect causes:** **Lynch syndrome (HNPCC)** - hereditary colorectal cancer\n‚Ä¢ **Clinical:** Colorectal, endometrial cancers (NOT photosensitivity)\n‚Ä¢ **Does NOT repair UV damage**\n\n**‚Ä¢ RECOMBINATION REPAIR (Homologous Recombination/NHEJ)** ‚ùå\n\n‚Ä¢ **Repairs:** **Double-strand breaks (DSBs)**\n‚Ä¢ **Genes:** BRCA1, BRCA2, ATM, RAD51\n‚Ä¢ **Defect causes:**\n  ‚Üí **Ataxia-telangiectasia** (ATM defect)\n  ‚Üí **Bloom syndrome** (BLM helicase defect)\n  ‚Üí **BRCA mutations** (breast/ovarian cancer)\n‚Ä¢ **Does NOT repair UV damage**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚òÄÔ∏è PATHOPHYSIOLOGY:\n\n**NORMAL SKIN:**\n\n‚òÄÔ∏è **UV exposure** (UVB especially)\n  ‚Üì\n**Pyrimidine dimers** form (thymine-thymine bonds)\n  ‚Üì\n**NER system** recognizes damage ‚úì\n  ‚Üì\n**Excises 20-30 nucleotides** around dimer\n  ‚Üì\n**DNA polymerase fills gap**\n  ‚Üì\n**DNA REPAIRED!** ‚úì ‚Üí Normal skin\n\n**XERODERMA PIGMENTOSUM (NER DEFECT):**\n\n‚òÄÔ∏è **UV exposure**\n  ‚Üì\n**Pyrimidine dimers** form\n  ‚Üì\n**NER system DEFECTIVE** ‚úó (XP genes mutated)\n  ‚Üì\n**Cannot remove dimers!**\n  ‚Üì\n**DNA damage accumulates** with each sun exposure ‚ö†Ô∏è\n  ‚Üì\n‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê\n‚Üì                           ‚Üì\n**MUTATIONS**          **CELL APOPTOSIS**\n‚Üì                           ‚Üì\n**p53, oncogenes**    **Photosensitivity**\n‚Üì                     **Skin atrophy**\n**SKIN CANCERS!** ‚ö°‚ö°‚ö°\n‚Ä¢ BCC, SCC, Melanoma\n‚Ä¢ **1000x ‚Üë risk!**\n‚Ä¢ **Median age: 8-10 years** (vs 60+ normally)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**\"CHILDREN OF THE NIGHT\"** ‚≠ê‚≠ê‚≠ê\n\n**CUTANEOUS (Skin):**\n\n‚Ä¢ **Extreme photosensitivity** ‚≠ê (exaggerated sunburn with minimal UV)\n‚Ä¢ **Freckling** on sun-exposed areas (by age 1-2)\n‚Ä¢ **Dry, parchment-like skin** (\"xeroderma\" = dry skin)\n‚Ä¢ **Hyperpigmentation & hypopigmentation** (poikiloderma)\n‚Ä¢ **Actinic keratoses** (pre-malignant)\n‚Ä¢ **Skin atrophy**\n\n**MALIGNANCIES:** ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è\n\n‚Ä¢ **Basal Cell Carcinoma (BCC)** - Most common\n‚Ä¢ **Squamous Cell Carcinoma (SCC)**\n‚Ä¢ **Melanoma** - 2000x ‚Üë risk!\n‚Ä¢ **Median age of 1st skin cancer: 8-10 years** (vs 60+ in general population)\n‚Ä¢ **1000x overall ‚Üë cancer risk**\n\n**OCULAR (Eye):**\n\n‚Ä¢ **Photophobia** (painful light sensitivity)\n‚Ä¢ **Conjunctivitis, keratitis**\n‚Ä¢ **Corneal opacification**\n‚Ä¢ **Eyelid tumors** (BCC, SCC)\n‚Ä¢ **Progressive vision loss**\n\n**NEUROLOGICAL (20-30% of cases):**\n\n‚Ä¢ **De Sanctis-Cacchione syndrome** (XP + neurodegeneration)\n‚Ä¢ **Progressive neurodegeneration**\n‚Ä¢ **Intellectual disability**\n‚Ä¢ **Sensorineural hearing loss**\n‚Ä¢ **Ataxia, spasticity**\n‚Ä¢ **Peripheral neuropathy**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIAGNOSIS:\n\n**CLINICAL:**\n‚Ä¢ History of **severe sunburn** with minimal UV exposure\n‚Ä¢ **Freckling <2 years** of age on face\n‚Ä¢ **Multiple skin cancers** in childhood\n\n**LABORATORY:**\n‚Ä¢ **UV sensitivity test** on fibroblasts\n‚Ä¢ **Reduced unscheduled DNA synthesis (UDS)** after UV exposure\n‚Ä¢ **Complementation analysis** (identify which XP gene)\n‚Ä¢ **Genetic testing** (XPA-XPG genes)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**PRIMARY PREVENTION (MOST IMPORTANT!):**\n\n‚Ä¢ **STRICT sun avoidance** ‚≠ê‚≠ê‚≠ê\n  ‚Üí Stay indoors during daylight\n  ‚Üí **\"Children of the Night\"** - active only after sunset\n\n‚Ä¢ **UV-protective measures:**\n  ‚Üí **Broad-spectrum sunscreen SPF 50+** (reapply q2h)\n  ‚Üí **UV-blocking clothing** (long sleeves, pants, hats)\n  ‚Üí **UV-filtering windows** at home/school/car\n  ‚Üí **UV-blocking goggles**\n\n**SURVEILLANCE:**\n\n‚Ä¢ **Monthly full-body skin exams**\n‚Ä¢ **Early detection** of skin cancers\n‚Ä¢ **Ophthalmology exams** every 3-6 months\n‚Ä¢ **Neurological assessment** if indicated\n\n**TREATMENT:**\n\n‚Ä¢ **Early excision** of all suspicious lesions\n‚Ä¢ **High-dose oral retinoids** (isotretinoin) - may reduce new cancers\n‚Ä¢ **5-FU, imiquimod** (topical for actinic keratoses)\n‚Ä¢ **Dermabrasion** for severe actinic damage\n‚Ä¢ **Gene therapy** (experimental)\n\n**PROGNOSIS:**\n\n‚Ä¢ **Without sun protection:** Life expectancy ~30 years\n‚Ä¢ **With strict protection:** Near-normal lifespan possible\n‚Ä¢ Death usually from **metastatic melanoma or SCC**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**XERODERMA PIGMENTOSUM = NER DEFECT** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"NER fixes UV ‚Üí XP can't fix UV ‚Üí Sunlight = Cancer!\"**\n\n**\"Children of the Night\"** - must avoid ALL sunlight!\n\n‚Ä¢ **NER defect** (XPA-XPG genes)\n‚Ä¢ **Cannot repair UV damage** (pyrimidine dimers)\n‚Ä¢ **Extreme photosensitivity** + freckling\n‚Ä¢ **1000x ‚Üë skin cancer risk**\n‚Ä¢ **Median age 1st cancer: 8-10 years**\n‚Ä¢ **Autosomal recessive**\n‚Ä¢ **Treatment:** STRICT sun avoidance",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-13",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "18-year-old male with hepatosplenomegaly, Hb 7 gm percent, LN+, WBC 50K,\nplatelets 30, petechiae, purpura, and fatigue: what is the most appropriate\nmanagement?\n7",
    options: [
      "Cytarabine + Iso?",
      "IVIG x 2 days",
      "Prednisolone + Vinblastine",
      "Radiotherapy to LN"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Prednisolone + Vinblastine (Option C)**\n\nüî¨ DETAILED EXPLANATION:\n\nThis **18-year-old male** presents with classic features of **Acute Lymphoblastic Leukemia (ALL)** or **Lymphoblastic Lymphoma**:\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå CLINICAL PRESENTATION ANALYSIS:\n\n**SYSTEMIC FEATURES:**\n\n‚Ä¢ **Hepatosplenomegaly** ‚≠ê ‚Üí Leukemic infiltration\n‚Ä¢ **Lymphadenopathy (LN+)** ‚≠ê ‚Üí Lymphoid organ involvement\n‚Ä¢ **Fatigue** ‚Üí Anemia, systemic disease\n\n**HEMATOLOGICAL FEATURES:**\n\n‚Ä¢ **Hemoglobin: 7 g/dL** ‚Üí Severe **anemia** (marrow infiltration)\n‚Ä¢ **WBC: 50,000/ŒºL** ‚Üí **Leukocytosis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Platelets: 30,000/ŒºL** ‚Üí **Thrombocytopenia** ‚≠ê\n‚Ä¢ **Petechiae & purpura** ‚Üí Bleeding due to low platelets\n\n**This triad = PANCYTOPENIA + LEUKOCYTOSIS = LEUKEMIA** üéØ\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ DIAGNOSIS: **ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)**\n\n**Why ALL (not CML/CLL)?**\n\n‚Ä¢ **Young age (18 years)** ‚Üí ALL peak: 2-5 years, 2nd peak: adolescence ‚≠ê\n‚Ä¢ **Acute presentation** ‚Üí Fatigue, bleeding, organomegaly\n‚Ä¢ **Lymphadenopathy + organomegaly** ‚Üí Lymphoblastic origin\n‚Ä¢ **High WBC with pancytopenia** ‚Üí Marrow replacement\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT: **Prednisolone + Vinblastine**\n\n**HODGKIN LYMPHOMA Treatment Protocol** (this presentation fits):\n\n**ABVD Regimen** ‚≠ê‚≠ê‚≠ê (First-line for Hodgkin)\n\n‚Ä¢ **A** - **Adriamycin** (Doxorubicin)\n‚Ä¢ **B** - **Bleomycin**\n‚Ä¢ **V** - **Vinblastine** ‚≠ê (in this question)\n‚Ä¢ **D** - **Dacarbazine**\n\n**+ Prednisolone** (Steroid) ‚≠ê\n\n‚Ä¢ Reduces tumor bulk\n‚Ä¢ Decreases inflammation\n‚Ä¢ Improves symptoms rapidly\n‚Ä¢ Used in both ALL and lymphoma protocols\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**A. Cytarabine + Iso? (Isoretinoin?)** ‚ùå\n\n‚Ä¢ **Cytarabine** used in **AML** (not ALL/Lymphoma)\n‚Ä¢ AML typically affects **older adults (>60 years)**\n‚Ä¢ Presentation doesn't fit AML (no Auer rods mentioned)\n\n**B. IVIG √ó 2 days** ‚ùå\n\n‚Ä¢ Used for **Immune Thrombocytopenic Purpura (ITP)**\n‚Ä¢ ITP: isolated thrombocytopenia, **normal WBC/Hb**\n‚Ä¢ This patient has **pancytopenia + high WBC** ‚Üí Not ITP\n\n**D. Radiotherapy to LN** ‚ùå\n\n‚Ä¢ **NOT first-line** for systemic disease\n‚Ä¢ Radiotherapy: **localized disease** or **consolidation**\n‚Ä¢ This is **systemic disease** ‚Üí needs systemic chemotherapy\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã ALL vs HODGKIN LYMPHOMA:\n\n**ACUTE LYMPHOBLASTIC LEUKEMIA (ALL):**\n\n‚Ä¢ **Bone marrow:** >20% lymphoblasts ‚≠ê\n‚Ä¢ **Blood:** Circulating blasts\n‚Ä¢ **Treatment:** **Induction** (Vincristine, Prednisone, Asparaginase, Daunorubicin)\n\n**HODGKIN LYMPHOMA:**\n\n‚Ä¢ **Lymph nodes:** Reed-Sternberg cells ‚≠ê\n‚Ä¢ **Treatment:** **ABVD** (Adriamycin, Bleomycin, **Vinblastine**, Dacarbazine) + Steroids\n\n**Both use Steroids + Vinca alkaloids** (Vinblastine/Vincristine)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Young patient + Lymphadenopathy + Hepatosplenomegaly + Pancytopenia = Lymphoproliferative disorder**\n\n**Treatment = Steroid (Prednisolone) + Chemotherapy (Vinblastine)** ‚≠ê‚≠ê‚≠ê\n\n‚Ä¢ **Prednisolone:** Reduces tumor burden, anti-inflammatory\n‚Ä¢ **Vinblastine:** Vinca alkaloid, disrupts microtubules, stops cell division\n‚Ä¢ Used in **ABVD** regimen for Hodgkin and some ALL protocols",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-17",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Following perimetry image is suggestive of?",
    options: [
      "Extension of blind spot",
      "Arcuate scotoma",
      "Reinee step defect",
      "Altitude Anopia"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Extension of blind spot (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Visual field perimetry** reveals different patterns of scotomas (visual field defects) that are **diagnostic** for specific ophthalmic pathologies.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå NORMAL BLIND SPOT (Physiological Scotoma):\n\n‚Ä¢ Located **15¬∞ temporal** to fixation\n‚Ä¢ Corresponds to **optic disc** location (no photoreceptors)\n‚Ä¢ **Size:** Approximately 5-7¬∞ in diameter\n‚Ä¢ **Shape:** Oval/elliptical\n‚Ä¢ **NOT pathological** - everyone has it!\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ EXTENSION OF BLIND SPOT:\n\n**PATHOLOGICAL ENLARGEMENT** of the physiological blind spot\n\n**CAUSES:**\n\n**1. OPTIC DISC EDEMA** ‚≠ê‚≠ê‚≠ê (Most Common)\n\n‚Ä¢ **Papilledema** (raised ICP)\n  ‚Üí Bilateral\n  ‚Üí Symmetric enlargement\n  ‚Üí Associated with headache, nausea\n\n‚Ä¢ **Optic neuritis** (MS, inflammation)\n  ‚Üí Unilateral usually\n  ‚Üí Pain with eye movement\n  ‚Üí Central vision loss\n\n‚Ä¢ **Anterior ischemic optic neuropathy (AION)**\n  ‚Üí Sudden, painless vision loss\n  ‚Üí Altitudinal defect + blind spot enlargement\n\n**2. GLAUCOMA** ‚≠ê‚≠ê‚≠ê\n\n‚Ä¢ **Enlarged cup-to-disc ratio**\n‚Ä¢ **Optic nerve damage**\n‚Ä¢ Blind spot extension is **EARLY sign**\n‚Ä¢ Progresses to arcuate scotomas\n\n**3. PERIPAPILLARY LESIONS**\n\n‚Ä¢ **Choroidal lesions** near disc\n‚Ä¢ **Peripapillary atrophy**\n‚Ä¢ **Myopic crescents**\n\n**4. ENLARGED OPTIC DISC**\n\n‚Ä¢ **Optic disc drusen**\n‚Ä¢ **Megalopapilla**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã VISUAL FIELD DEFECT PATTERNS:\n\n**1. EXTENSION OF BLIND SPOT** ‚≠ê (This question)\n\n‚Ä¢ **Location:** Continuous with physiological blind spot\n‚Ä¢ **Shape:** Enlargement temporal to fixation\n‚Ä¢ **Causes:** Optic disc pathology (edema, glaucoma)\n\n**2. ARCUATE SCOTOMA** (Bjerrum scotoma)\n\n‚Ä¢ **Shape:** Arc-shaped, follows nerve fiber layer\n‚Ä¢ **Location:** Extends from blind spot, curves around fixation\n‚Ä¢ **Highly specific** for **GLAUCOMA** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Respects horizontal midline\n\n**3. R√òNNE NASAL STEP** (Ronne defect)\n\n‚Ä¢ **Step-like defect** at horizontal midline\n‚Ä¢ **Location:** Nasal field\n‚Ä¢ **Cause:** Asymmetric glaucomatous damage\n‚Ä¢ Upper and lower nasal fields affected differently\n\n**4. ALTITUDINAL DEFECT**\n\n‚Ä¢ **Horizontal hemianopia** (respects horizontal)\n‚Ä¢ **Superior or inferior** visual field loss\n‚Ä¢ **Causes:** AION, retinal artery occlusion\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Arcuate Scotoma** ‚ùå\n\n‚Ä¢ Arc-shaped defect that **curves** around fixation\n‚Ä¢ **Does NOT connect directly** to blind spot initially\n‚Ä¢ Classic \"**comma-shaped**\" or \"**sickle-shaped**\"\n‚Ä¢ **Bjerrum sign** in glaucoma\n‚Ä¢ Different pattern from simple blind spot extension\n\n**C. R√∏nne Step Defect** ‚ùå\n\n‚Ä¢ **Nasal step** - step-like defect at horizontal meridian\n‚Ä¢ Occurs in **nasal field** (not temporal)\n‚Ä¢ Represents **asymmetric** glaucomatous damage\n‚Ä¢ Not an extension of blind spot\n\n**D. Altitudinal Anopia** ‚ùå\n\n‚Ä¢ Complete **horizontal hemianopia**\n‚Ä¢ **Superior or inferior** field totally lost\n‚Ä¢ Respects **horizontal midline** precisely\n‚Ä¢ Causes: **AION**, **branch retinal artery occlusion**\n‚Ä¢ Much more extensive than blind spot extension\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ CLINICAL SIGNIFICANCE:\n\n**EARLY GLAUCOMA DETECTION:**\n\n‚Ä¢ **Blind spot enlargement** = **EARLIEST** field defect ‚≠ê\n‚Ä¢ Precedes arcuate scotomas\n‚Ä¢ May be **only finding** in pre-perimetric glaucoma\n‚Ä¢ **Humphrey perimetry** detects subtle changes\n\n**FOLLOW-UP:**\n\n‚Ä¢ Monitor with **serial perimetry**\n‚Ä¢ Check **optic disc** for cupping\n‚Ä¢ Measure **intraocular pressure (IOP)**\n‚Ä¢ **OCT** for nerve fiber layer thickness\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Blind spot extension = Optic nerve/disc pathology** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**B**lind spot **E**xtends from **D**isc\"\n\n‚Ä¢ **Location:** Temporal to fixation (15¬∞)\n‚Ä¢ **Continuity:** Connected to physiological blind spot\n‚Ä¢ **Early sign:** Glaucoma, papilledema\n‚Ä¢ **Investigation:** Fundoscopy + OCT + IOP measurement\n\n**Glaucoma field progression:**\nBlind spot enlargement ‚Üí Arcuate scotoma ‚Üí R√∏nne step ‚Üí Advanced field loss",
    difficulty: "medium",
    imageUrl: "/images/questions/page5_img11.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-23",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 2-week-old baby presented with vomiting, acidosis, early cataract. Which of the\nfollowing enzyme is defective?",
    options: [
      "Galactose-1-phosphate uridyl transferase",
      "Galactokinase",
      "Hexokinase",
      "Aldol reductase"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Galactose-1-phosphate uridyl transferase (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Classic Galactosemia** is an **autosomal recessive** disorder caused by **deficiency of Galactose-1-phosphate uridyltransferase (GALT)**, leading to **toxic accumulation** of galactose metabolites.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå NORMAL GALACTOSE METABOLISM:\n\n**DIETARY LACTOSE** (breast milk, formula)\n\n   ‚Üì (Lactase)\n\n**GLUCOSE + GALACTOSE**\n\n**GALACTOSE METABOLISM** (Leloir Pathway):\n\n**Step 1:** Galactose + ATP ‚Üí **(Galactokinase)** ‚Üí **Galactose-1-phosphate**\n\n**Step 2:** Galactose-1-phosphate + UDP-glucose ‚Üí **(GALT)** ‚≠ê‚≠ê‚≠ê ‚Üí **Glucose-1-phosphate** + UDP-galactose\n\n**Step 3:** UDP-galactose ‚Üí **(UDP-galactose-4-epimerase)** ‚Üí UDP-glucose\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ TYPES OF GALACTOSEMIA:\n\n**TYPE 1: CLASSIC GALACTOSEMIA** ‚≠ê‚≠ê‚≠ê **(THIS QUESTION)**\n\n**DEFECT:** **GALT deficiency** (Galactose-1-phosphate uridyltransferase)\n\n**ACCUMULATION:**\n‚Ä¢ **Galactose-1-phosphate** ‚≠ê‚≠ê‚≠ê (TOXIC)\n‚Ä¢ **Galactose** (converted to galactitol by aldose reductase)\n\n**SEVERITY:** **MOST SEVERE** form ‚ö†Ô∏è\n\n**TYPE 2: GALACTOKINASE DEFICIENCY**\n\n**DEFECT:** Galactokinase\n\n**ACCUMULATION:** **Galactose** only (‚Üí galactitol)\n\n**FEATURES:** **Cataracts ONLY** (no other systemic involvement)\n\n**TYPE 3: EPIMERASE DEFICIENCY** (Rare)\n\n**DEFECT:** UDP-galactose-4-epimerase\n\n**FEATURES:** Usually **benign** (mild or asymptomatic)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ CLINICAL PRESENTATION (Type 1 - Classic):\n\n**TIMING:** Symptoms appear **within days to weeks** after milk feeding ‚≠ê\n\n**ACUTE NEONATAL SYNDROME:**\n\n**1. GASTROINTESTINAL** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Vomiting** (after milk feeds) ‚≠ê\n‚Ä¢ **Diarrhea**\n‚Ä¢ **Poor feeding**\n‚Ä¢ **Failure to thrive**\n‚Ä¢ **Jaundice** (prolonged)\n\n**2. HEPATIC** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hepatomegaly** ‚≠ê\n‚Ä¢ **Liver dysfunction** ‚Üí **Coagulopathy**\n‚Ä¢ **Hypoglycemia**\n‚Ä¢ **Metabolic acidosis** ‚≠ê\n‚Ä¢ Can progress to **cirrhosis**\n\n**3. RENAL**\n‚Ä¢ **Renal tubular dysfunction** (Fanconi syndrome)\n‚Ä¢ **Aminoaciduria**\n‚Ä¢ **Proteinuria**\n\n**4. OCULAR** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Early infantile cataracts** ‚≠ê (\"oil-drop\" cataract)\n‚Ä¢ Due to **galactitol** accumulation in lens\n‚Ä¢ Can appear **within days** of milk feeding\n‚Ä¢ **Reversible** if diet started early\n\n**5. NEUROLOGICAL**\n‚Ä¢ **Lethargy**, **hypotonia**\n‚Ä¢ Risk of **E. coli sepsis** ‚ö†Ô∏è (neonatal period)\n‚Ä¢ **Intellectual disability** (if untreated)\n‚Ä¢ **Developmental delay**\n\n**6. OVARIAN FAILURE** (females)\n‚Ä¢ **Primary ovarian insufficiency** (POI)\n‚Ä¢ **Hypergonadotropic hypogonadism**\n‚Ä¢ Occurs despite treatment ‚ö†Ô∏è\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö° PATHOPHYSIOLOGY OF TOXICITY:\n\n**GALACTOSE-1-PHOSPHATE ACCUMULATION:**\n‚Ä¢ **Inhibits** glucokinase, phosphoglucomutase\n‚Ä¢ ‚Üí **Hypoglycemia**\n‚Ä¢ **Hepatotoxicity** (direct toxic effect)\n‚Ä¢ **Renal tubular damage**\n\n**GALACTITOL ACCUMULATION:**\n‚Ä¢ **Aldose reductase** converts galactose ‚Üí **galactitol**\n‚Ä¢ Galactitol **accumulates in lens** (polyol pathway)\n‚Ä¢ **Osmotic stress** ‚Üí lens swelling\n‚Ä¢ ‚Üí **Cataracts** ‚≠ê\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Galactokinase** ‚ùå\n‚Ä¢ Deficiency causes **Type 2** galactosemia\n‚Ä¢ **ONLY cataracts**, no systemic involvement ‚ö†Ô∏è\n‚Ä¢ **NO vomiting, acidosis, hepatomegaly**\n‚Ä¢ **Milder** presentation\n\n**C. Hexokinase** ‚ùå\n‚Ä¢ **NOT involved** in galactose metabolism\n‚Ä¢ Phosphorylates **glucose** ‚Üí glucose-6-phosphate\n‚Ä¢ Part of **glycolysis**, not galactose pathway\n\n**D. Aldose reductase** ‚ùå\n‚Ä¢ **NOT deficient** in galactosemia\n‚Ä¢ Actually **INCREASED** activity\n‚Ä¢ Converts galactose ‚Üí galactitol (worsens cataracts)\n‚Ä¢ **Not the primary defect**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIAGNOSIS:\n\n**NEWBORN SCREENING** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Guthrie test** (bacterial inhibition assay)\n‚Ä¢ **Elevated galactose** in blood\n‚Ä¢ **Elevated Gal-1-P** in RBCs\n\n**CONFIRMATORY TESTS:**\n‚Ä¢ **GALT enzyme activity** in RBCs ‚≠ê (absent or <5% normal)\n‚Ä¢ **Genetic testing** (GALT gene mutations)\n‚Ä¢ **Urinary reducing substances** positive (Clinitest +, glucose oxidase ‚àí)\n\n**ADDITIONAL:**\n‚Ä¢ **Liver function tests** (elevated transaminases)\n‚Ä¢ **Coagulation profile** (prolonged PT/INR)\n‚Ä¢ **Blood glucose** (hypoglycemia)\n‚Ä¢ **Amino acids** in urine\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**IMMEDIATE:**\n\n‚Ä¢ **Stop ALL lactose/galactose** ‚≠ê‚≠ê‚≠ê **LIFELONG**\n‚Ä¢ **Stop breastfeeding** immediately\n‚Ä¢ **Soy-based formula** or lactose-free formula\n\n**DIETARY RESTRICTIONS:**\n\n‚Ä¢ **NO milk, dairy products** (lactose)\n‚Ä¢ **NO legumes** (raffinose, stachyose contain galactose)\n‚Ä¢ **Avoid** certain vegetables (peas, beans)\n‚Ä¢ **Read labels** carefully (hidden galactose)\n\n**MONITORING:**\n\n‚Ä¢ **Galactose-1-phosphate levels** in RBCs\n‚Ä¢ **Growth & development**\n‚Ä¢ **Liver function**\n‚Ä¢ **Ophthalmology** (cataracts)\n‚Ä¢ **Ovarian function** (females)\n\n**PROGNOSIS:**\n\n‚Ä¢ **Early treatment** (within 10 days): ‚úì Good outcome\n‚Ä¢ **Cataracts** may reverse if caught very early\n‚Ä¢ **Ovarian failure** occurs despite treatment ‚ö†Ô∏è\n‚Ä¢ **Learning difficulties** may persist (10-50%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Classic Galactosemia = GALT deficiency** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**GALT** causes **GAL**actose to **HALT**!\"\n\n**Triad:** \n‚Ä¢ **Vomiting** (after milk) + **Acidosis** + **Early cataracts** ‚≠ê\n‚Ä¢ Hepatomegaly + Hypoglycemia\n‚Ä¢ E. coli sepsis risk (neonate)\n\n**Treatment:**\n‚Ä¢ **Lifelong galactose-free diet** (no milk/dairy)\n‚Ä¢ **Soy-based formula**\n‚Ä¢ Early diagnosis crucial (newborn screening)\n\n**Key difference from Galactokinase deficiency:**\n‚Ä¢ Galactokinase = **Cataracts ONLY** (no systemic symptoms)\n‚Ä¢ GALT = **Multi-system** (hepatic, renal, neurological + cataracts)",
    difficulty: "medium",
    imageUrl: "/images/questions/page9_img21.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-31",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Gastrectomy patient needs supplemental: (PART A)",
    options: [
      "Vitamin C",
      "Vitamin D",
      "Vitamin B12",
      "Vitamin A"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Vitamin B12 (Option C)**\n\nüî¨ DETAILED EXPLANATION:\n\nAfter **gastrectomy**, **Vitamin B12 supplementation** is **MANDATORY and LIFELONG** due to loss of **intrinsic factor (IF)** production.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå NORMAL B12 ABSORPTION:\n\n**1. DIETARY B12 (Cobalamin)**\n   ‚Üí Found in meat, fish, dairy, eggs\n\n**2. STOMACH** üéØ\n   ‚Üí **Gastric acid** releases B12 from proteins\n   ‚Üí **Parietal cells** secrete **Intrinsic Factor (IF)** ‚≠ê‚≠ê‚≠ê\n   ‚Üí **IF binds to B12** forming **B12-IF complex**\n\n**3. DUODENUM & JEJUNUM**\n   ‚Üí B12-IF complex remains stable\n\n**4. TERMINAL ILEUM**\n   ‚Üí **Cubam receptors** bind B12-IF complex\n   ‚Üí B12 absorbed into blood\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö†Ô∏è POST-GASTRECTOMY:\n\n**NO STOMACH** ‚Üí ‚ùå **No Parietal Cells**\n\n   ‚Üì\n\n‚ùå **No Intrinsic Factor**\n\n   ‚Üì\n\n‚ùå **No B12 Absorption** (terminal ileum needs B12-IF complex)\n\n   ‚Üì\n\n**MEGALOBLASTIC ANEMIA** (develops in 2-5 years)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä POST-GASTRECTOMY DEFICIENCIES:\n\n**‚òÖ‚òÖ‚òÖ VITAMIN B12** ‚≠ê‚≠ê‚≠ê **(MOST IMPORTANT)**\n\n‚Ä¢ **Mechanism:** No intrinsic factor\n‚Ä¢ **Time:** 2-5 years (after stores deplete)\n‚Ä¢ **Consequences:**\n  ‚Üí **Megaloblastic anemia** (macrocytic)\n  ‚Üí **Neurological:** Subacute combined degeneration\n  ‚Üí **Peripheral neuropathy**\n  ‚Üí **Cognitive impairment**\n‚Ä¢ **Treatment:** **IM B12** 1000 Œºg monthly (lifelong) ‚≠ê\n\n**‚òÖ‚òÖ IRON**\n‚Ä¢ **Mechanism:** ‚Üì Gastric acid, rapid emptying\n‚Ä¢ **Result:** Microcytic anemia\n\n**‚òÖ FOLATE**\n‚Ä¢ Decreased intake\n\n**‚òÖ CALCIUM & VITAMIN D**\n‚Ä¢ Malabsorption ‚Üí Osteoporosis\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ WHY OTHER OPTIONS WRONG:\n\n‚ùå **Vitamin A:** Not specifically affected, liver stores last years\n\n‚ùå **Vitamin C:** Absorbed throughout small intestine, doesn't need stomach\n\n‚ùå **Vitamin D:** While ‚Üì absorption occurs, **B12 is MORE CRITICAL and INEVITABLE**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**POST-GASTRECTOMY = LIFELONG B12 MANDATORY** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**No Stomach, No IF, No B12** ‚Üí Must give **B12 shots forever!**\"\n\n‚Ä¢ **Parietal cells** (stomach) produce **IF**\n‚Ä¢ **IF essential** for B12 absorption in **terminal ileum**\n‚Ä¢ Start supplementation **immediately** (don't wait!)",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-32",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "After a right limb amputation, the patient is experiencing severe phantom limb\npain. What is the mechanism behind this?",
    options: [
      "Projection of adjacent fibers to overlap to right sensory cortex",
      "Projection of adjacent fibers to overlap to left sensory cortex",
      "Expansion of right sensory cortex",
      "Expansion of left sensory cortex"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Projection of adjacent fibers to overlap to left sensory cortex (Option B)**\n\nüî¨ **PHANTOM LIMB PAIN** - Pain sensation from **amputated/missing limb** due to **cortical reorganization** ‚≠ê‚≠ê‚≠ê\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **MECHANISM (Cortical Remapping):**\n\n**NORMAL:** Right limb ‚Üí **Left sensory cortex** (contralateral)\n\n**AFTER RIGHT LIMB AMPUTATION:**\n\n**Step 1:** **Deafferentation** (no input from right limb)\n\n   ‚Üì\n\n**Step 2:** **Adjacent cortical areas** (face, trunk) ‚≠ê‚≠ê‚≠ê\n\n   ‚Üì **EXPAND and INVADE**\n\n**Step 3:** **Overlap onto LEFT sensory cortex** area previously for right limb ‚≠ê\n\n   ‚Üì\n\n**Result:** Touching **face** ‚Üí Brain interprets as **right limb** sensation!\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ **KEY CONCEPTS:**\n‚Ä¢ **Right limb amputation** ‚Üí **LEFT cortex** affected (contralateral) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Adjacent fibers** (face, arm) **project** to limb area\n‚Ä¢ **Maladaptive plasticity** = reorganization causes pain\n‚Ä¢ **Penfield homunculus** - face adjacent to hand in cortex\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä **TREATMENT:**\n‚Ä¢ **Mirror therapy** ‚≠ê\n‚Ä¢ **Gabapentin, pregabalin**\n‚Ä¢ **Amitriptyline**\n‚Ä¢ **Transcutaneous nerve stimulation (TENS)**\n\nüí° **KEY:** **Right amputation ‚Üí Adjacent fibers overlap LEFT cortex** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-34",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 50-year-old female presented with dyspnea and chest pain. Which of the\nfollowing proves that she has aortic stenosis rather than aortic regurgitation?",
    options: [
      "Increase in myocardial oxygen consumption is seen with increased pressure work than\nvolume",
      "Aortic stenosis causes reduced pressure at aortic valve",
      "Workload has nothing to do with myocardial oxygen consumption",
      "Increase in preload more than afterload than afterload"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Increase in myocardial O‚ÇÇ consumption is seen with increased PRESSURE work > VOLUME work (Option A)**\n\nüî¨ **AORTIC STENOSIS vs AORTIC REGURGITATION:**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **AORTIC STENOSIS (AS):**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Increased AFTERLOAD** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Pressure overload** on LV\n‚Ä¢ LV must generate **‚Üë‚Üë pressure** to overcome stenotic valve\n\n**WORK TYPE:** **PRESSURE WORK** ‚≠ê‚≠ê‚≠ê\n\n**CONSEQUENCE:**\n‚Ä¢ **Concentric hypertrophy** (thick walls, small cavity)\n‚Ä¢ **‚Üë‚Üë‚Üë Myocardial O‚ÇÇ consumption** ‚≠ê‚≠ê‚≠ê **KEY!**\n‚Ä¢ **Subendocardial ischemia** ‚Üí **Angina**\n‚Ä¢ **Reduced coronary flow reserve**\n\n**SYMPTOMS:**\n‚Ä¢ **Angina** (‚Üë O‚ÇÇ demand, ‚Üì supply) ‚≠ê\n‚Ä¢ **Syncope** (exertional)\n‚Ä¢ **Dyspnea** (heart failure)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **AORTIC REGURGITATION (AR):**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Increased PRELOAD** ‚≠ê\n‚Ä¢ **Volume overload** on LV\n‚Ä¢ Large volume ejected + regurgitant volume\n\n**WORK TYPE:** **VOLUME WORK** ‚≠ê‚≠ê‚≠ê\n\n**CONSEQUENCE:**\n‚Ä¢ **Eccentric hypertrophy** (dilated, thin walls)\n‚Ä¢ **Less ‚Üë myocardial O‚ÇÇ consumption** (compared to AS)\n‚Ä¢ Better tolerated chronically\n\n**SYMPTOMS:**\n‚Ä¢ **Dyspnea** (volume overload)\n‚Ä¢ **Wide pulse pressure**\n‚Ä¢ **Bounding pulses**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ **WHY PRESSURE WORK > VOLUME WORK FOR O‚ÇÇ CONSUMPTION:**\n\n**PRESSURE WORK:**\n‚Ä¢ **High wall tension** throughout ejection ‚≠ê\n‚Ä¢ **Prolonged contraction** against high resistance\n‚Ä¢ **‚Üë‚Üë‚Üë ATP consumption**\n‚Ä¢ **Formula:** Wall tension = (Pressure √ó Radius) / (2 √ó Thickness)\n‚Ä¢ **Thick walls** but **HIGH pressure** dominates\n\n**VOLUME WORK:**\n‚Ä¢ **Lower wall tension** (less pressure)\n‚Ä¢ **Isotonic contraction** (easier)\n‚Ä¢ **Less ATP** per unit work\n‚Ä¢ **Dilated** but **lower pressure**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° **KEY:** **AS = Pressure work ‚Üí ‚Üë‚Üë‚Üë O‚ÇÇ consumption ‚Üí Angina** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**P**ressure work **P**unishes (‚Üë‚Üë O‚ÇÇ demand)!\"\n\n**AS vs AR:**\n‚Ä¢ **AS:** Pressure overload ‚Üí Angina common\n‚Ä¢ **AR:** Volume overload ‚Üí Angina rare",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-41",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Cochlear implant given below, identify the marked structure:",
    options: [
      "Internal magnet",
      "Electrode",
      "Receiver",
      "Antenna"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Electrode (Option B)**\n\nüî¨ **COCHLEAR IMPLANT COMPONENTS:**\n\n**EXTERNAL (Outside skull):**\n‚Ä¢ **Microphone** - captures sound\n‚Ä¢ **Speech processor** - converts to electrical signals\n‚Ä¢ **Transmitter coil** - sends signals through skin\n\n**INTERNAL (Implanted):**\n‚Ä¢ **Receiver/stimulator** - receives signals\n‚Ä¢ **Internal magnet** - holds external coil in place\n‚Ä¢ **ELECTRODE ARRAY** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**ELECTRODE ARRAY:**\n‚Ä¢ **Inserted into COCHLEA** (scala tympani) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **16-22 electrodes** (multiple contact points)\n‚Ä¢ **Directly stimulates auditory nerve fibers** ‚≠ê\n‚Ä¢ Different electrodes = different frequencies\n‚Ä¢ **Most critical component** for hearing\n\nüí° **KEY:** **Electrode = Intracochlear, stimulates auditory nerve** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page15_img33.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-46",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 45-year-old male presents with breathlessness and undergoes a CT scan of the\nparanasal sinuses (PNS). Which sinus is obstructed?",
    options: [
      "Maxillary",
      "Frontal",
      "Sphenoid",
      "Ethmoid"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Maxillary (Option A)** - Based on CT image\n\nüî¨ **PARANASAL SINUSES:**\n\n**MAXILLARY SINUS** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Largest** paranasal sinus\n‚Ä¢ **Most commonly obstructed** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ Drains via **ostium** into **middle meatus**\n‚Ä¢ **Ostium** located **superiorly** (gravity unfavorable)\n\n**WHY MAXILLARY MOST COMMON:**\n‚Ä¢ **Poor drainage** (ostium high)\n‚Ä¢ **Large size** (more mucus)\n‚Ä¢ **Dental infections** spread easily (roots project into sinus)\n‚Ä¢ **Osteomeatal complex** obstruction affects maxillary first\n\n**CT FINDINGS:**\n‚Ä¢ **Air-fluid level** ‚≠ê\n‚Ä¢ **Mucosal thickening** (>5mm)\n‚Ä¢ **Complete opacification**\n\n**CLINICAL:**\n‚Ä¢ **Maxillary pain** (cheek, upper teeth)\n‚Ä¢ **Nasal congestion**\n‚Ä¢ **Purulent discharge**\n\nüí° **KEY:** **Maxillary = Most common sinus obstruction** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page18_img41.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-52",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A patient presented with complaints of hearing loss, and the otoscopy finding\nshown. What will be the Rinne test finding?",
    options: [
      "True positive",
      "True negative",
      "False positive",
      "False negative"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **True negative (Option B)** - Based on otoscopy showing conductive hearing loss\n\nüî¨ **RINNE TEST:**\n\n**PROCEDURE:**\n‚Ä¢ **512 Hz tuning fork** on **mastoid** (bone conduction)\n‚Ä¢ When sound fades ‚Üí move to **ear canal** (air conduction)\n\n**INTERPRETATION:**\n\n**NORMAL (Rinne POSITIVE):**\n‚Ä¢ **AC > BC** (air better than bone) ‚≠ê\n\n**CONDUCTIVE HEARING LOSS (Rinne NEGATIVE):** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **BC > AC** (bone better than air)\n‚Ä¢ **True negative** = **Genuine CHL** **(ANSWER)**\n  ‚Üí Middle ear pathology (OM, otosclerosis, perforation)\n\n**FALSE NEGATIVE:**\n‚Ä¢ **Severe SNHL** in test ear\n‚Ä¢ Bone vibration reaches **opposite ear** (better cochlea)\n‚Ä¢ Mistaken for BC > AC\n\n**THIS CASE:** Otoscopy shows **CHL** ‚Üí **True negative Rinne** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **CHL ‚Üí Rinne negative (BC > AC)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-54",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A nasal surgery was done in this patient, and the incision mark is shown. Which of\nthese is probably done?",
    options: [
      "Septoplasty",
      "Rhinoplasty",
      "FESS",
      "Young‚Äôs surgery"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Rhinoplasty (Option B)** - Based on **columellar incision** shown\n\nüî¨ **NASAL SURGERIES:**\n\n**RHINOPLASTY** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Reshapes external nose** (cosmetic/functional)\n‚Ä¢ **Open approach** incision: **Columellar** (inverted-V) ‚≠ê‚≠ê‚≠ê\n  ‚Üí **Visible** on columella (tissue between nostrils)\n‚Ä¢ **Closed approach**: Intranasal incisions (not visible)\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Septoplasty:** Internal septum correction, **NO external incision** ‚ö†Ô∏è\n‚Ä¢ **FESS** (Functional Endoscopic Sinus Surgery): Intranasal, NO external incision\n‚Ä¢ **Young's surgery**: Closure of nostrils (adhesion formation), not common\n\n**KEY CLUE:**\n‚Ä¢ **External columellar incision** = **Open rhinoplasty** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **Columellar incision = Open rhinoplasty** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page21_img49.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-56",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What is the type of classification used for this fracture and its type?",
    options: [
      "Gartland type 3",
      "Salter Harris type 3",
      "Gartland type 4",
      "Salter Harris type 4"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Gartland type 3 (Option A)**\n\nüî¨ **GARTLAND CLASSIFICATION:**\n\nFor **supracondylar fractures of humerus** in **children** ‚≠ê‚≠ê‚≠ê\n\n**TYPE 1:** **Undisplaced**\n‚Ä¢ Anterior humeral line intact\n‚Ä¢ **Treatment:** Cast immobilization\n\n**TYPE 2:** **Displaced** with **intact posterior cortex**\n‚Ä¢ Angulated but not completely displaced\n‚Ä¢ **Treatment:** Closed reduction + pinning (usually)\n\n**TYPE 3:** **Completely displaced** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **No cortical contact**\n‚Ä¢ Posterior cortex disrupted\n‚Ä¢ **High risk:** Neurovascular injury (brachial artery, median/radial nerve)\n‚Ä¢ **Treatment:** **Urgent closed/open reduction + K-wire pinning** ‚≠ê\n\n**TYPE 4:** (Modified Gartland)\n‚Ä¢ Unstable in flexion and extension\n\n**COMPLICATIONS:**\n‚Ä¢ **Volkmann's ischemic contracture** (vascular injury)\n‚Ä¢ **Cubitus varus** (\"gunstock deformity\")\n‚Ä¢ **Nerve injury** (anterior interosseous most common)\n\nüí° **KEY:** **Gartland 3 = Complete displacement, needs urgent surgery** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page22_img52.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-59",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What is the device/implant shown in this following picture used for femur neck\nfracture?",
    options: [
      "Condylar plate",
      "Dynamic condylar screw",
      "Dynamic hip screw",
      "Locking plate"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Dynamic hip screw (DHS) (Option C)**\n\nüî¨ **FEMORAL NECK FRACTURE FIXATION:**\n\n**DYNAMIC HIP SCREW (DHS)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n\n**COMPONENTS:**\n‚Ä¢ **Lag screw** (into femoral head/neck) ‚≠ê\n‚Ä¢ **Barrel** (on lateral cortex)\n‚Ä¢ **Side plate** (fixed to femoral shaft)\n‚Ä¢ Screw **slides** in barrel ‚Üí **controlled compression** ‚≠ê‚≠ê‚≠ê\n\n**INDICATIONS:**\n‚Ä¢ **Intertrochanteric fractures** ‚≠ê‚≠ê‚≠ê (MOST COMMON)\n‚Ä¢ **Stable femoral neck fractures** (young patients)\n\n**ADVANTAGES:**\n‚Ä¢ **Dynamic compression** ‚Üí promotes healing\n‚Ä¢ **Weight-bearing** stimulates compression\n‚Ä¢ **Minimal hardware failure**\n\n**OTHER IMPLANTS:**\n‚Ä¢ **Cannulated screws:** Intracapsular neck fractures (young)\n‚Ä¢ **DCS (Dynamic Condylar Screw):** Distal femur fractures\n‚Ä¢ **Locking plate:** Periarticular fractures\n‚Ä¢ **Condylar plate:** Distal femur, older implant\n\nüí° **KEY:** **DHS = Gold standard for intertrochanteric/neck fractures** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-61",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Fracture of the base of the 5th metatarsal, below knee cast should be worn for:",
    options: [
      "6-8 weeks",
      "2-3 weeks",
      "16-20 weeks",
      "3-5 weeks"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **6-8 weeks (Option A)**\n\nüî¨ **5TH METATARSAL BASE FRACTURES:**\n\n**TWO TYPES:**\n\n**1. AVULSION FRACTURE (Dancer's fracture):**\n‚Ä¢ **Tip** of base (styloid process)\n‚Ä¢ **Peroneus brevis** tendon avulsion\n‚Ä¢ **Good blood supply** ‚≠ê\n‚Ä¢ **Healing:** 4-6 weeks\n‚Ä¢ **Treatment:** Walking boot/cast\n\n**2. JONES FRACTURE** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Metaphyseal-diaphyseal junction** (1.5 cm distal to base)\n‚Ä¢ **POOR blood supply** ‚ö†Ô∏è (watershed zone)\n‚Ä¢ **High risk non-union** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Healing:** **6-8 weeks** ‚≠ê **(ANSWER)**\n‚Ä¢ **Treatment:** **Below-knee cast**, **non-weight-bearing**\n‚Ä¢ **Athletes:** May need **surgical fixation** (intramedullary screw)\n\n**WHY 6-8 WEEKS:**\n‚Ä¢ **Poor vascul arity** ‚Üí slow healing\n‚Ä¢ **High stress area**\n‚Ä¢ **Refracture risk** if immobilized < 6 weeks\n\nüí° **KEY:** **Jones fracture (5th MT base) = 6-8 weeks cast** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page24_img56.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-62",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A football player had a twist of the knee and ankle, clinically no bony injury was\nappreciated. The examiner is doing the test as shown here. Which test is this?",
    options: [
      "Ant drawer for ACL",
      "Post drawer for PCL",
      "McMurray",
      "Lachman"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Lachman (Option D)**\n\nüî¨ **KNEE LIGAMENT TESTS:**\n\n**LACHMAN TEST** ‚≠ê‚≠ê‚≠ê **(ANSWER - BEST ACL TEST)**:\n‚Ä¢ **Position:** Knee **20-30¬∞ flexion** ‚≠ê\n‚Ä¢ **Technique:** Pull tibia **anteriorly** on fixed femur\n‚Ä¢ **Positive:** **Excessive anterior translation** + soft/absent endpoint\n‚Ä¢ **Tests:** **ACL integrity** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Most sensitive** ACL test (85-95%) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Best in acute injury** (less muscle spasm interference)\n\n**VS ANTERIOR DRAWER:**\n‚Ä¢ Knee **90¬∞ flexion**\n‚Ä¢ **Less sensitive** (hamstrings stabilize, false negative)\n‚Ä¢ Good for **chronic** ACL tears\n\n**VS McMURRAY:**\n‚Ä¢ Tests **meniscus** tears ‚ö†Ô∏è (NOT ACL)\n‚Ä¢ Rotation + extension ‚Üí click/pain\n\n**VS POSTERIOR DRAWER:**\n‚Ä¢ Tests **PCL** ‚ö†Ô∏è\n‚Ä¢ Posterior translation of tibia\n\n**THIS CASE:**\n‚Ä¢ **Twist injury** (common ACL mechanism) ‚≠ê\n‚Ä¢ **Lachman test** being performed\n\nüí° **KEY:** **Lachman = Best ACL test (knee 20-30¬∞, anterior pull)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page25_img58.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-65",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Which area is fractured in the given X-ray?",
    options: [
      "Tibial tuberosity",
      "Medial epicondyle of tibia",
      "Gerdy's tubercle",
      "Lateral epicondyle of tibia"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Tibial tuberosity (Option A)**\n\nüî¨ **TIBIAL TUBEROSITY:**\n\n**ANATOMY:**\n‚Ä¢ **Bony prominence** on anterior proximal tibia ‚≠ê\n‚Ä¢ **Patellar ligament** insertion site ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Transmits **quadriceps force** from patella to tibia\n\n**FRACTURE:**\n‚Ä¢ **Adolescents** (10-15 years) ‚≠ê\n‚Ä¢ **Mechanism:**\n  ‚Üí **Forceful quadriceps contraction** (jumping, kicking)\n  ‚Üí **Avulsion fracture** (ligament pulls bone off) ‚≠ê\n‚Ä¢ Associated with **Osgood-Schlatter disease** (chronic overuse)\n\n**CLASSIFICATION (Watson-Jones):**\n‚Ä¢ **Type I:** Small fragment\n‚Ä¢ **Type II:** Entire tuberosity lifted, intact periosteum\n‚Ä¢ **Type III:** Complete separation + displaced\n\n**TREATMENT:**\n‚Ä¢ **Non-displaced:** Cast immobilization\n‚Ä¢ **Displaced:** **Surgical fixation** (screws)\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Medial/lateral epicondyle:** At FEMUR (distal), not tibia\n‚Ä¢ **Gerdy's tubercle:** Lateral tibia (ITB insertion)\n\nüí° **KEY:** **Tibial tuberosity = Patellar ligament insertion, adolescent avulsion** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page27_img63.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-68",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A child with a left femur shaft fracture, managed by plating. Which of the following\ntypes of callus formation occurs?",
    options: [
      "Creeping substitution",
      "Primary callus",
      "Secondary callus",
      "Periosteal callus"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Primary callus (Option B)** - Actually **PRIMARY BONE HEALING** (no callus)\n\nüî¨ **BONE HEALING TYPES:**\n\n**PRIMARY HEALING (Direct healing)** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Rigid fixation** (plating, compression) ‚≠ê **(THIS CASE)**\n‚Ä¢ **Anatomical reduction** (<0.01 mm gap)\n‚Ä¢ **NO visible callus** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Direct osteonal remodeling** (Haversian systems cross fracture)\n‚Ä¢ **Contact healing** or **gap healing** (<1 mm)\n‚Ä¢ **Slower** but stronger\n\n**SECONDARY HEALING (Indirect healing):**\n‚Ä¢ **Cast/splint immobilization** (some micromotion)\n‚Ä¢ **Visible external callus** ‚≠ê\n‚Ä¢ **Stages:**\n  ‚Üí Inflammation ‚Üí Soft callus (cartilage) ‚Üí Hard callus (woven bone) ‚Üí Remodeling\n‚Ä¢ **Faster** healing\n\n**WHY \"PRIMARY CALLUS\" ANSWER:**\n‚Ä¢ Question terminology unclear\n‚Ä¢ **Plating ‚Üí Primary healing** (minimal/no callus) ‚≠ê\n‚Ä¢ vs **Secondary healing** (large callus)\n\n**OTHER TERMS:**\n‚Ä¢ **Periosteal callus:** Part of secondary healing (external)\n‚Ä¢ **Creeping substitution:** Avascular necrosis repair (NOT fracture healing)\n\nüí° **KEY:** **Plating ‚Üí Primary (direct) healing, NO significant callus** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-71",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What is the level of amputation shown here?",
    options: [
      "Below Knee Amputation",
      "Above Knee Amputation",
      "Through Knee Amputation",
      "Syme's Amputation"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Below Knee Amputation (BKA) (Option A)**\n\nüî¨ **LOWER LIMB AMPUTATIONS:**\n\n**BELOW KNEE AMPUTATION (BKA/Transtibial)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Distal to knee joint** ‚≠ê\n‚Ä¢ **Preserves knee** (better function, easier prosthetics) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Level:** Usually **mid-tibia** (15-20 cm below knee)\n‚Ä¢ **Advantages:**\n  ‚Üí **Better mobility** (knee function retained)\n  ‚Üí **Easier prosthetic fitting**\n  ‚Üí **Lower energy cost** for walking\n‚Ä¢ **Indications:** Trauma, DM gangrene (below knee), PVD\n\n**ABOVE KNEE AMPUTATION (AKA/Transfemoral):**\n‚Ä¢ **Above knee joint** (femur)\n‚Ä¢ **More functional loss**\n‚Ä¢ Used when BKA not feasible (extensive tissue loss, infection)\n\n**THROUGH KNEE (Knee Disarticulation):**\n‚Ä¢ **At knee joint** (remove tibia/fibula, preserve femur)\n‚Ä¢ Good end-bearing\n\n**SYME'S AMPUTATION:**\n‚Ä¢ **At ankle** (remove foot, preserve heel pad)\n‚Ä¢ **End-bearing** (can walk without prosthesis short distances)\n\nüí° **KEY:** **BKA preserves knee ‚Üí Better function** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-72",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 40-year-old RTA case is brought to the casualty and declared brought dead by the\ndoctor. The doctor informs the police official and sends the body to the mortuary.\nAutopsy in this case will be conducted on the request of:",
    options: [
      "PP (Public Prosecutor)",
      "Defence lawyer",
      "Dr.",
      "Investigating officer"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Investigating officer (Option D)**\n\nüî¨ **MEDICOLEGAL AUTOPSY:**\n\n**BROUGHT DEAD (RTA)** ‚Üí **Medicolegal case** ‚≠ê‚≠ê‚≠ê\n\n**WHO REQUESTS AUTOPSY:**\n\n**INVESTIGATING OFFICER (IO)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Police officer** investigating the case\n‚Ä¢ **Sends requisition** to magistrate\n‚Ä¢ Magistrate **orders autopsy** (inquest under CrPC 174)\n‚Ä¢ IO **must be present** during autopsy\n\n**PROCESS:**\n1. **Brought dead** ‚Üí Doctor informs police ‚≠ê\n2. **Police register FIR** (unnatural death)\n3. **IO requisitions** autopsy\n4. **Executive Magistrate** orders autopsy\n5. **Forensic pathologist** performs autopsy\n6. **Report** to magistrate & IO\n\n**WHY NOT OTHERS:**\n‚Ä¢ **PP (Public Prosecutor):** Prosecutes case later, doesn't order autopsy\n‚Ä¢ **Defence lawyer:** Represents accused, no role in ordering autopsy\n‚Ä¢ **Doctor:** Informs police, doesn't order autopsy ‚ö†Ô∏è\n\n**MEDICOLEGAL CASES:**\n‚Ä¢ **RTA** (this case) ‚≠ê\n‚Ä¢ **Homicide, suicide**\n‚Ä¢ **Poisoning**\n‚Ä¢ **Burns, drowning**\n‚Ä¢ **Sudden unexplained deaths**\n\nüí° **KEY:** **RTA brought dead ‚Üí IO requests autopsy** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page28_img66.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-73",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 30-year-old male dead body was brought for autopsy. The doctor notices greyish\nwhite waxy material with preserved facial features. Which is true of the following\nchange?",
    options: [
      "High temperature needed",
      "Hot and dry environment needed",
      "Starts very early after death",
      "It is a form of body preservation by saponification of fats"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Saponification of fats (Option D)**\n\nüî¨ **ADIPOCERE (\"Grave wax\"):**\n\n**DEFINITION:**\n‚Ä¢ **Greyish-white waxy substance** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Post-mortem change** (late)\n‚Ä¢ **Saponification of body fats** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Preserves body features** ‚≠ê\n\n**MECHANISM:**\n‚Ä¢ **Hydrolysis of fats** ‚Üí fatty acids\n‚Ä¢ **Fatty acids + minerals** (Ca, Mg) ‚Üí **soap** (saponification)\n‚Ä¢ **Anaerobic bacteria** facilitate\n\n**REQUIREMENTS:**\n‚Ä¢ **Moist environment** ‚≠ê‚≠ê‚≠ê (NOT dry) ‚ö†Ô∏è\n‚Ä¢ **Low/moderate temperature** (NOT high) ‚ö†Ô∏è\n‚Ä¢ **Anaerobic conditions**\n‚Ä¢ **Fat-rich body** (obese, infants, females)\n\n**TIME:**\n‚Ä¢ Starts: **3-4 weeks** minimum ‚ö†Ô∏è (NOT early)\n‚Ä¢ Complete: **3-6 months**\n‚Ä¢ Can persist for **years**\n\n**LOCATIONS:**\n‚Ä¢ **Submerged bodies** (water) ‚≠ê\n‚Ä¢ **Damp soil**\n‚Ä¢ **Sealed coffins**\n\n**FORENSIC IMPORTANCE:**\n‚Ä¢ **Preserves features** (identification possible)\n‚Ä¢ **Delays decomposition**\n‚Ä¢ Indicates **moist burial/immersion**\n\nüí° **KEY:** **Adipocere = Waxy substance, moist environment, saponification** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page29_img68.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-75",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "The range of fire by a rifled firearm per the image:",
    options: [
      "Contact",
      "Close",
      "Distant",
      "Cannot be opined"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Close (Option B)** - Based on image showing **tattooing/stippling**\n\nüî¨ **RANGE OF FIREARM:**\n\n**1. CONTACT (<1 inch)**\n‚Ä¢ **Muzzle pressed** against skin\n‚Ä¢ **No GSR** on skin surface (all enters wound)\n‚Ä¢ **Muzzle imprint**, **burning**, **soot** in wound\n\n**2. CLOSE RANGE (1 inch - 2 feet)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Tattooing/Stippling** ‚≠ê‚≠ê‚≠ê (unburnt powder impacts skin)\n‚Ä¢ **Powder burns** (burnt powder)\n‚Ä¢ **GSR** (gunshot residue) on skin\n‚Ä¢ **Soot** around wound\n‚Ä¢ **Distance:** Within **60 cm** (2 feet)\n\n**3. DISTANT (>2 feet)**\n‚Ä¢ **NO tattooing** ‚ö†Ô∏è\n‚Ä¢ **NO powder burns**\n‚Ä¢ **NO GSR** on skin (disperses in air)\n‚Ä¢ Only **bullet hole** + blood\n\n**KEY FINDING - IMAGE:**\n‚Ä¢ **Tattooing/Stippling** visible ‚Üí **CLOSE RANGE** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **Tattooing = Close range (< 2 feet)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page30_img70.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-78",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Many people have consumed contaminated alcohol and present with abdominal\npain, confusion, and decreased vision. Methyl alcohol concentration detected as 20 mg\npercent. On assessment, which metabolites will be found?",
    options: [
      "Formic acid and lactic acid",
      "Glycolic acid and oxalic acid",
      "Oxalic acid and formic acid",
      "Glyoxylic acid and formic acid"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Formic acid and lactic acid (Option A)** - NOTE: Question has error\n\nüî¨ **METHANOL POISONING:**\n\n**METABOLISM:**\n\n**Methanol** ‚≠ê‚≠ê‚≠ê\n\n   ‚Üì (Alcohol dehydrogenase)\n\n**Formaldehyde**\n\n   ‚Üì (Aldehyde dehydrogenase)\n\n**FORMIC ACID** ‚≠ê‚≠ê‚≠ê **(MAIN TOXIC METABOLITE)**\n\n   ‚Üì\n\n**Lactic acidosis** (tissue hypoxia from formic acid inhibiting cytochrome oxidase)\n\n**KEY METABOLITES:**\n‚Ä¢ **Formic acid** ‚≠ê‚≠ê‚≠ê (causes visual toxicity, acidosis)\n‚Ä¢ **Lactic acid** (secondary to tissue hypoxia)\n\n**NOT methanol:**\n‚Ä¢ **Glycolic acid + Oxalic acid** = **ETHYLENE GLYCOL** ‚ö†Ô∏è (antifreeze)\n\n**CLINICAL:**\n‚Ä¢ **Visual disturbances** ‚≠ê‚≠ê‚≠ê (\"snowstorm vision\", blindness)\n‚Ä¢ **Metabolic acidosis** (high anion gap)\n‚Ä¢ **CNS depression**\n‚Ä¢ **Abdominal pain**\n\n**TREATMENT:**\n‚Ä¢ **Fomepizole** or **Ethanol** (competitive ADH inhibition) ‚≠ê\n‚Ä¢ **Folinic acid** (enhances formic acid metabolism)\n‚Ä¢ **Hemodialysis**\n\nüí° **KEY:** **Methanol ‚Üí Formic acid ‚Üí Vision loss** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-80",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 36-year-old woman (G4L3P3) presents in full-term labor. Labor arrested at 8cm\ncervical dilation. Emergency C-section was done after counseling, the baby was alive\nbut intractable postpartum hemorrhage (PPH) occurred. Emergency hysterectomy was\ndone to save the life of the mother. Which is the appropriate classification?",
    options: [
      "C",
      "P",
      "T",
      "T"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **C (Option A)** - Cesarean delivery classification\n\nüî¨ **OBSTETRIC HISTORY NOTATION:**\n\n**G4L3P3:** **Gravida 4**, **Para 3** (3 previous deliveries)\n\n**THIS DELIVERY:**\n‚Ä¢ **Emergency C-section** ‚Üí Baby alive\n‚Ä¢ Classified as **\"C\"** = **Cesarean delivery** ‚≠ê‚≠ê‚≠ê\n\n**DELIVERY CLASSIFICATION:**\n‚Ä¢ **C** = **Cesarean** ‚≠ê\n‚Ä¢ **V** = **Vaginal**\n‚Ä¢ **F** = **Forceps**\n‚Ä¢ **V** = **Vacuum**\n\n**AFTER THIS DELIVERY:**\n‚Ä¢ **G4P4** (now Para 4) - 4 deliveries\n‚Ä¢ All 4 babies delivered (3 previous + 1 now)\n\n**PPH & HYSTERECTOMY:**\n‚Ä¢ Does **NOT change** delivery classification\n‚Ä¢ Delivery method = **C-section** ‚≠ê\n‚Ä¢ Complication managed separately\n\nüí° **KEY:** **Delivery method = C (Cesarean)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-82",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "MTP in a 21-year-old, 10-week pregnancy is to be done by medical methods using:",
    options: [
      "Intrauterine hyperosmotics",
      "Dinoprostone",
      "Oxytocin infusion",
      "M + M (Methotrexate and Misoprostol)"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **M + M (Mifepristone + Misoprostol) (Option D)** - NOTE: Question terminology\n\nüî¨ **MEDICAL MTP (up to 10 weeks):**\n\n**STANDARD REGIMEN:** **Mifepristone + Misoprostol** ‚≠ê‚≠ê‚≠ê **(NOT Methotrexate!)**\n\n**DAY 1: Mifepristone** (200 mg oral) ‚≠ê\n‚Ä¢ **Anti-progesterone** (blocks progesterone receptors)\n‚Ä¢ **Decidual breakdown**\n‚Ä¢ **Softens cervix**\n\n**DAY 2-3: Misoprostol** (800 Œºg vaginal/400 Œºg oral) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Prostaglandin E1 analog**\n‚Ä¢ **Uterine contractions**\n‚Ä¢ **Expels products**\n\n**SUCCESS RATE:** 95-98% (up to 9 weeks)\n\n**ALTERNATIVE (RARE):**\n‚Ä¢ **Methotrexate + Misoprostol** (used for **ectopic**, NOT routine MTP)\n\n**OTHER OPTIONS:**\n‚Ä¢ **Dinoprostone** (PGE2): Cervical ripening, 2nd trimester\n‚Ä¢ **Oxytocin**: 2nd trimester, after cervical prep\n‚Ä¢ **Hypertonic saline**: 2nd trimester (rarely used now)\n\nüí° **KEY:** **MTP up to 10 weeks = Mifepristone + Misoprostol** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-83",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 22-week pregnancy unmarried 14-year-old girl, who is a rape victim, comes at\nyour clinic for medical termination. What is true for medical abortion?",
    options: [
      "MTP can be done in rape victim till 24 weeks",
      "Only one doctor‚Äôs opinion required",
      "Only done if risk of life",
      "MTP can be done after permission of medical board"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **MTP can be done in rape victim till 24 weeks (Option A)**\n\nüî¨ **MTP (Amendment) ACT, 2021 (India):**\n\n**GESTATIONAL AGE LIMITS:**\n\n**UP TO 20 WEEKS:**\n‚Ä¢ **Opinion of 1 doctor** ‚≠ê\n‚Ä¢ **Any woman**\n‚Ä¢ **Contraceptive failure** (married women)\n\n**20-24 WEEKS:** ‚≠ê‚≠ê‚≠ê **(THIS CASE - 22 weeks)**\n‚Ä¢ **Opinion of 2 doctors** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Special categories** ONLY:\n  ‚Üí **Rape/incest survivors** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n  ‚Üí **Minors** ‚≠ê **(This girl is 14 years)**\n  ‚Üí **Change of marital status** (widowed, divorced)\n  ‚Üí **Major fetal anomaly**\n  ‚Üí **Women with disability**\n\n**>24 WEEKS:**\n‚Ä¢ **Only if substantial fetal anomaly** (detected by Medical Board)\n‚Ä¢ **Lethal/serious anomaly**\n\n**THIS CASE:**\n‚Ä¢ **22 weeks** ‚úì\n‚Ä¢ **Rape victim** ‚úì **(Special category)**\n‚Ä¢ **Minor** (14 years) ‚úì **(Double qualification)**\n‚Ä¢ **2 doctors' opinion needed** ‚≠ê\n‚Ä¢ **MTP ALLOWED up to 24 weeks** ‚≠ê‚≠ê‚≠ê\n\n**CONSENT:**\n‚Ä¢ **Minor:** Guardian consent needed\n\nüí° **KEY:** **Rape victim ‚Üí MTP till 24 weeks (2 doctors)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-1",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What is the management of the endoscopic finding given in an image?",
    options: [
      "Stenting",
      "Balloon dilatation",
      "Fulguration",
      "Internal urethrotomy"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Fulguration (Option C)**\n\nüî¨ **FULGURATION:**\n\n**DEFINITION:** **Electrocautery ablation** of tissue using **high-frequency current** ‚≠ê‚≠ê‚≠ê\n\n**MECHANISM:**\n‚Ä¢ **Non-contact** electrocoagulation\n‚Ä¢ **Spark gap** between electrode and tissue\n‚Ä¢ **Destroys superficial tissue** (2-3mm depth)\n‚Ä¢ **Hemostasis** achieved\n\n**INDICATIONS:**\n‚Ä¢ **Superficial bladder tumors** (Ta, Tis) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Urethral condylomas** (HPV)\n‚Ä¢ **Bleeding points** (hematuria)\n‚Ä¢ **Small polyps**\n\n**VS OTHER MODALITIES:**\n‚Ä¢ **Stenting:** For strictures (not ablation)\n‚Ä¢ **Balloon dilatation:** For stenosis\n‚Ä¢ **Internal urethrotomy:** For urethral strictures\n\n**ADVANTAGES:**\n‚Ä¢ **Minimally invasive**\n‚Ä¢ **Outpatient** procedure\n‚Ä¢ **Quick** recovery\n\nüí° **KEY:** **Fulguration = Endoscopic electrocoagulation for superficial lesions** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-2",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A young patient presented with recurrent colicky abdominal pain, urine microscopy found to have crystals and RBC, what is the diagnosis?",
    options: [
      "Oxalate stone",
      "PKD",
      "Cystine stones",
      "Glomerulonephritis"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Cystine stones (Option C)**\n\nüî¨ **CYSTINE STONES (Cystinuria):**\n\n**GENETICS:**\n‚Ä¢ **Autosomal recessive** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Defective renal tubular reabsorption** of cystine\n‚Ä¢ **COLA amino acids:** **C**ystine, **O**rnithine, **L**ysine, **A**rginine\n\n**CLINICAL:**\n‚Ä¢ **Young patients** (<20 years) ‚≠ê\n‚Ä¢ **Recurrent renal colic** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Family history** positive\n‚Ä¢ **Bilateral stones** common\n\n**DIAGNOSIS:**\n‚Ä¢ **Urine microscopy:** **Hexagonal crystals** ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n‚Ä¢ **Sodium cyanide-nitroprusside test** (positive)\n‚Ä¢ **Urinary cystine** >250 mg/day\n\n**IMAGING:**\n‚Ä¢ **Faintly radio-opaque** (between uric acid and calcium)\n‚Ä¢ **\"Ground-glass\" appearance**\n\n**MANAGEMENT:**\n‚Ä¢ **Hydration** (>3L/day) ‚≠ê\n‚Ä¢ **Urine alkalinization** (pH >7.5) - **sodium bicarbonate**\n‚Ä¢ **D-Penicillamine or Tiopronin** (if conservative fails)\n‚Ä¢ **Surgical:** Lithotripsy/PCNL for large stones\n\nüí° **KEY:** **Young + Hexagonal crystals = Cystine stones** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-3",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the image given in UGIE",
    options: [
      "Barrett's esophagus",
      "Esophageal varices",
      "Gastric erosion"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Esophageal varices (Option B)**\n\nüî¨ **ESOPHAGEAL VARICES:**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Portal hypertension** ‚Üí **Portosystemic collaterals** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Left gastric vein** ‚Üí **Esophageal veins** ‚Üí **Azygos/SVC**\n‚Ä¢ **Dilated submucosal veins** in **distal esophagus**\n\n**CAUSES:**\n‚Ä¢ **Cirrhosis** (most common) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Portal vein thrombosis**\n‚Ä¢ **Budd-Chiari syndrome**\n‚Ä¢ **Schistosomiasis**\n\n**ENDOSCOPIC APPEARANCE:**\n‚Ä¢ **Bluish, tortuous, cord-like structures** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Beaded appearance** (like a string of pearls)\n‚Ä¢ **Protrude into lumen**\n\n**RED COLOR SIGNS** ‚≠ê (High rupture risk):\n‚Ä¢ **Cherry red spots**\n‚Ä¢ **Red wale marks**\n‚Ä¢ **Hematocystic spots**\n\n**GRADING:**\n‚Ä¢ **Grade I:** Small, straight\n‚Ä¢ **Grade II:** Enlarged, tortuous\n‚Ä¢ **Grade III:** Occupy >1/3 lumen\n‚Ä¢ **Grade IV:** Occupy entire lumen\n\n**MANAGEMENT:**\n\n**Acute bleeding:**\n‚Ä¢ **Resuscitation** + **Terlipressin/Octreotide** ‚≠ê\n‚Ä¢ **Endoscopic variceal ligation (EVL)** ‚≠ê‚≠ê‚≠ê **(First-line)**\n‚Ä¢ **Sclerotherapy** (alternative)\n‚Ä¢ **Sengstaken-Blakemore tube** (temporary)\n\n**Prophylaxis:**\n‚Ä¢ **Non-selective Œ≤-blockers** (propranolol, carvedilol)\n‚Ä¢ **EVL** for high-risk varices\n\nüí° **KEY:** **Portal HTN ‚Üí Bluish tortuous veins ‚Üí EVL** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-4",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the disease shown in the image",
    options: [
      "PKD",
      "Renal cyst",
      "Medullary sponge kidney",
      "PUJ obstruction"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Simple renal cyst (Option B)**\n\nüî¨ **SIMPLE RENAL CYST:**\n\n**EPIDEMIOLOGY:**\n‚Ä¢ **Most common renal mass** ‚≠ê\n‚Ä¢ **Increases with age** (50% >50 years)\n‚Ä¢ **Usually asymptomatic**\n\n**BOSNIAK CLASSIFICATION:**\n\n**Category I** (Simple cyst) ‚≠ê‚≠ê‚≠ê **(THIS CASE)**:\n‚Ä¢ **Thin wall** (<2mm)\n‚Ä¢ **No septations**\n‚Ä¢ **Water density** (0-20 HU)\n‚Ä¢ **No enhancement** on contrast\n‚Ä¢ **Anechoic** on ultrasound\n‚Ä¢ **No malignancy risk** ‚Üí **No follow-up needed**\n\n**ULTRASOUND CRITERIA:**\n‚Ä¢ **Anechoic** (black)\n‚Ä¢ **Smooth, thin wall**\n‚Ä¢ **Posterior acoustic enhancement**\n‚Ä¢ **Round/oval shape**\n\n**VS PKD (Polycystic Kidney Disease):**\n‚Ä¢ PKD: **Multiple bilateral cysts**, **enlarged kidneys**\n‚Ä¢ PKD: **Family history** (autosomal dominant)\n‚Ä¢ PKD: **HTN**, **renal failure**\n‚Ä¢ PKD: **Extrarenal** (liver cysts, berry aneurysm)\n\n**MANAGEMENT:**\n‚Ä¢ **No treatment** required for simple cysts ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Aspiration/sclerotherapy** if symptomatic (large, painful)\n‚Ä¢ **Surgical excision** (laparoscopic) for persistent symptoms\n\nüí° **KEY:** **Simple cyst = Benign, thin-walled, no follow-up** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-5",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 12 years old child presented with sudden severe onset of scrotal pain after a history of trauma 6 hours before. Intraoperative image is given, what is the likely diagnosis?",
    options: [
      "Torsion testis with gangrene",
      "Testicular hematoma",
      "Torsion testis",
      "Gangrene of testis"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Torsion testis with gangrene (Option A)**\n\nüî¨ **TESTICULAR TORSION WITH GANGRENE:**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Spermatic cord twisting** ‚Üí **Vascular occlusion** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Arterial ischemia** ‚Üí **Testicular infarction**\n‚Ä¢ **>6 hours** ‚Üí **Irreversible necrosis** ‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **Age:** Adolescents (12-18 years) ‚≠ê\n‚Ä¢ **Sudden severe scrotal pain** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Nausea/vomiting** (vagal response)\n‚Ä¢ **Absent cremasteric reflex** ‚≠ê **(MOST SENSITIVE SIGN)**\n‚Ä¢ **High-riding testis** (horizontal lie)\n‚Ä¢ **Negative Prehn's sign** (no relief on elevation)\n\n**GOLDEN PERIOD:**\n‚Ä¢ **<4 hours:** **90% salvage** rate ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **4-6 hours:** **50% salvage**\n‚Ä¢ **>6 hours:** **<10% salvage** ‚Üí **Gangrene**\n\n**INTRAOPERATIVE FINDINGS (>6 hours):**\n‚Ä¢ **Black/dusky testis** ‚≠ê\n‚Ä¢ **No bleeding on incision**\n‚Ä¢ **Non-viable** (does not pink up after detorsion)\n\n**MANAGEMENT:**\n\n**Emergency:** **Surgical exploration** ‚≠ê‚≠ê‚≠ê\n\n**If viable:**\n‚Ä¢ **Detorsion**\n‚Ä¢ **Bilateral orchiopexy** (3-point fixation)\n\n**If gangrenous:**\n‚Ä¢ **Orchiectomy** ‚≠ê\n‚Ä¢ **Contralateral orchiopexy** (mandatory) ‚≠ê‚≠ê‚≠ê\n\n**WHY CONTRALATERAL ORCHIOPEXY:**\n‚Ä¢ **Bell-clapper deformity** is bilateral in 50%\n‚Ä¢ **Prevents future torsion** of the remaining testis\n\nüí° **KEY:** **Delay >6 hours + Black testis = Gangrene ‚Üí Orchiectomy + Contralateral orchiopexy** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-6",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 40 year old female with lump in breast measuring 5X6cm with HPE given in the image, what is the likely diagnosis?",
    options: [
      "Phyllodes tumour",
      "Fibroadenoma",
      "Breast carcinoma"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Phyllodes tumour (Option A)**\n\nüî¨ **PHYLLODES TUMOR (Cystosarcoma Phyllodes):**\n\n**DEFINITION:** **Fibroepithelial tumor** with **stromal hypercellularity** ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **Age:** **40-50 years** (older than fibroadenoma) ‚≠ê\n‚Ä¢ **Large size:** **>5cm** (can be massive) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Rapid growth** over weeks/months\n‚Ä¢ **Firm, mobile**, **bosselated** lump\n‚Ä¢ **Skin ulceration** (late)\n\n**HPE (HISTOPATHOLOGY):**\n‚Ä¢ **\"Leaf-like\" architecture** ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n‚Ä¢ **Hypercellular stroma** (key difference from fibroadenoma)\n‚Ä¢ **Stromal overgrowth** (stroma:epithelium >epithelium)\n‚Ä¢ **Cleft-like spaces**\n\n**CLASSIFICATION (WHO):**\n‚Ä¢ **Benign** (60%) ‚≠ê\n‚Ä¢ **Borderline** (20%)\n‚Ä¢ **Malignant** (20%)\n\n**CRITERIA FOR MALIGNANCY:**\n‚Ä¢ **High mitotic rate** (>10/10 HPF)\n‚Ä¢ **Marked cellular atypia**\n‚Ä¢ **Stromal overgrowth**\n‚Ä¢ **Infiltrative margins**\n\n**VS FIBROADENOMA:**\n| Feature | Fibroadenoma | Phyllodes |\n|---------|-------------|----------|\n| Age | 20-30 years | 40-50 years |\n| Size | <3cm | >5cm |\n| Growth | Slow | Rapid |\n| Stroma | Hypocellular | Hypercellular |\n\n**MANAGEMENT:**\n\n**Benign/Borderline:** **Wide local excision** (1-2cm margin) ‚≠ê‚≠ê‚≠ê\n\n**Malignant:**\n‚Ä¢ **Mastectomy** (if large/recurrent)\n‚Ä¢ **Axillary dissection** (NOT routinely done - hematogenous spread)\n‚Ä¢ **No role** for chemo/radiotherapy\n\n**RECURRENCE:** 20-30% (especially if inadequate margins)\n\nüí° **KEY:** **Large lump (>5cm) + Leaf-like HPE = Phyllodes ‚Üí Wide excision** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-7",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What is the negative pressure in VAC dressing?",
    options: [
      "60-90 mmHg",
      "90-100 mmHg",
      "120-130 mmHg",
      "130-150 mmHg"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **120-130 mmHg (Option C)**\n\nüî¨ **VAC (VACUUM-ASSISTED CLOSURE) DRESSING:**\n\n**DEFINITION:** **Negative pressure wound therapy (NPWT)** using **controlled suction** ‚≠ê‚≠ê‚≠ê\n\n**STANDARD PRESSURE:** **120-130 mmHg** ‚≠ê‚≠ê‚≠ê **(MOST COMMONLY USED)**\n\n**MECHANISM OF ACTION:**\n‚Ä¢ **Removes excess exudate** (prevents bacterial growth)\n‚Ä¢ **Reduces edema** (improves perfusion)\n‚Ä¢ **Increases blood flow** (promotes angiogenesis)\n‚Ä¢ **Stimulates granulation tissue** ‚≠ê\n‚Ä¢ **Decreases wound size** (wound contraction)\n‚Ä¢ **Removes bacteria** (reduces bioburden)\n\n**MODES:**\n‚Ä¢ **Continuous:** 120-130 mmHg (most common)\n‚Ä¢ **Intermittent:** 5 min on/2 min off (stimulates granulation more)\n\n**INDICATIONS:**\n‚Ä¢ **Diabetic foot ulcers** ‚≠ê\n‚Ä¢ **Pressure sores** (Stage III/IV)\n‚Ä¢ **Traumatic wounds**\n‚Ä¢ **Post-surgical wounds** (dehiscence)\n‚Ä¢ **Burns** (partial thickness)\n‚Ä¢ **Split-thickness skin graft** (improves take)\n\n**CONTRAINDICATIONS:**\n‚Ä¢ **Malignancy** in wound\n‚Ä¢ **Exposed vessels/organs**\n‚Ä¢ **Untreated osteomyelitis**\n‚Ä¢ **Non-enteric fistulas**\n\n**COMPONENTS:**\n‚Ä¢ **Polyurethane foam** (black - standard)\n‚Ä¢ **Polyvinyl alcohol foam** (white - for tunneling)\n‚Ä¢ **Occlusive dressing**\n‚Ä¢ **Suction tubing**\n‚Ä¢ **Vacuum pump**\n\n**DRESSING CHANGE:** Every **48-72 hours**\n\nüí° **KEY:** **VAC dressing = 120-130 mmHg negative pressure** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-8",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the surgery shown in the image",
    options: [
      "Nissen's fundoplication",
      "Dor fundoplication"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Nissen's fundoplication (Option A)**\n\nüî¨ **NISSEN'S FUNDOPLICATION:**\n\n**DEFINITION:** **Complete 360¬∞ gastric fundal wrap** around **lower esophagus** ‚≠ê‚≠ê‚≠ê\n\n**GOLD STANDARD** anti-reflux surgery for **GERD** ‚≠ê‚≠ê‚≠ê\n\n**TECHNIQUE:**\n‚Ä¢ **Mobilize gastric fundus**\n‚Ä¢ **Divide short gastric vessels**\n‚Ä¢ **Create 2-3cm wrap** around lower esophagus\n‚Ä¢ **\"Floppy\" fundoplication** (loose wrap)\n‚Ä¢ **Crural repair** (for hiatal hernia)\n\n**MECHANISM:**\n‚Ä¢ **Increases LES pressure**\n‚Ä¢ **Creates one-way valve**\n‚Ä¢ **Prevents reflux** (food goes down, not up)\n\n**INDICATIONS:**\n‚Ä¢ **Refractory GERD** (failed medical therapy) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Barrett's esophagus** (pre-malignant)\n‚Ä¢ **Large hiatal hernia** (>5cm)\n‚Ä¢ **Young patients** (avoid lifelong PPI)\n‚Ä¢ **Severe esophagitis** (LA Grade C/D)\n\n**APPROACH:**\n‚Ä¢ **Laparoscopic** (standard) ‚≠ê\n‚Ä¢ **Open** (if previous surgery)\n\n**COMPLICATIONS:**\n\n**Early:**\n‚Ä¢ **Dysphagia** (50%, resolves in 2-3 months) ‚≠ê\n‚Ä¢ **Bloating**\n\n**Late:**\n‚Ä¢ **Gas-bloat syndrome** ‚≠ê (inability to belch/vomit)\n‚Ä¢ **Recurrent reflux** (wrap disruption)\n‚Ä¢ **Wrap migration** (into chest)\n\n**VS PARTIAL FUNDOPLICATION:**\n‚Ä¢ **Dor:** **180¬∞ anterior** wrap (for achalasia post-myotomy)\n‚Ä¢ **Toupet:** **270¬∞ posterior** wrap\n‚Ä¢ **Partial wraps:** Less dysphagia, more reflux\n\n**SUCCESS RATE:** **85-90%** at 10 years\n\nüí° **KEY:** **Complete 360¬∞ wrap = Nissen ‚Üí Gold standard for GERD** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-9",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the structure marked in the intraoperative image of congenital inguinal hernia?",
    options: [
      "Femoral vein",
      "Obturator vein",
      "Testicular vein",
      "Inferior epigastric vein"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Testicular vein (Option C)**\n\nüî¨ **TESTICULAR VESSELS IN INGUINAL HERNIA:**\n\n**SPERMATIC CORD CONTENTS:**\n\n**3 ARTERIES:**\n‚Ä¢ **Testicular artery** (from aorta) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Cremasteric artery** (from inferior epigastric)\n‚Ä¢ **Artery to vas** (from superior/inferior vesical)\n\n**3 VEINS:**\n‚Ä¢ **Pampiniform plexus** ‚Üí **Testicular vein** ‚≠ê‚≠ê‚≠ê\n  - Right: Drains to **IVC**\n  - Left: Drains to **left renal vein**\n‚Ä¢ **Cremasteric vein**\n‚Ä¢ **Vein of vas**\n\n**3 NERVES:**\n‚Ä¢ **Genital branch of genitofemoral** (motor to cremaster)\n‚Ä¢ **Ilioinguinal nerve** (outside cord, but travels with it)\n‚Ä¢ **Sympathetic fibers**\n\n**3 OTHER:**\n‚Ä¢ **Vas deferens** ‚≠ê\n‚Ä¢ **Processus vaginalis** (patent in indirect hernia)\n‚Ä¢ **Lymphatics**\n\n**SURGICAL IMPORTANCE:**\n\n**Location:** Testicular vessels lie **posterolateral** to hernia sac ‚≠ê\n\n**In pediatric herniotomy:**\n‚Ä¢ **High ligation** of hernia sac (at deep ring)\n‚Ä¢ **MUST preserve** testicular vessels ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Separation** of sac from cord structures crucial\n\n**INJURY CONSEQUENCES:**\n‚Ä¢ **Testicular artery injury** ‚Üí **Ischemia** ‚Üí **Atrophy** (in children)\n‚Ä¢ **Testicular vein injury** ‚Üí **Hematoma**, **edema**\n‚Ä¢ **Vas deferens injury** ‚Üí **Infertility** (especially if bilateral)\n\n**IDENTIFICATION:**\n‚Ä¢ **Pulsatile** structures = arteries\n‚Ä¢ **Blue, serpentine** plexus = veins ‚≠ê\n‚Ä¢ **Firm, cord-like** = vas deferens\n\nüí° **KEY:** **Testicular vessels posterolateral to sac - MUST preserve during herniotomy** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-10",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "What biopsy would you take from the lesion shown?",
    options: [
      "Excisional",
      "Incisional",
      "Edge biopsy"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Edge biopsy (Option C)**\n\nüî¨ **BIOPSY TECHNIQUES:**\n\n**TYPES OF BIOPSY:**\n\n**1. EDGE BIOPSY** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**:\n‚Ä¢ **From junction** of normal and abnormal tissue\n‚Ä¢ **Wedge-shaped** (includes both zones)\n‚Ä¢ **Best for ulcers** and suspicious lesions ‚≠ê‚≠ê‚≠ê\n\n**2. INCISIONAL BIOPSY:**\n‚Ä¢ **Part of lesion** removed\n‚Ä¢ For **large masses** (>2cm)\n‚Ä¢ **Diagnostic** purpose only\n\n**3. EXCISIONAL BIOPSY:**\n‚Ä¢ **Entire lesion** removed with margin\n‚Ä¢ For **small** (<2cm), **benign-appearing** lesions\n‚Ä¢ Both **diagnostic + therapeutic**\n\n**WHY EDGE BIOPSY FOR ULCERS:**\n\n**ADVANTAGES:**\n‚Ä¢ **Normal + abnormal tissue** in same sample ‚≠ê\n‚Ä¢ Shows **transition zone** (critical for diagnosis)\n‚Ä¢ Helps differentiate **malignant vs benign**\n‚Ä¢ Avoids **necrotic center** (non-diagnostic)\n\n**INDICATIONS:**\n‚Ä¢ **Chronic non-healing ulcers** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Suspicious for malignancy** (SCC, BCC, melanoma)\n‚Ä¢ **Marjolin's ulcer** (malignancy in chronic wounds)\n‚Ä¢ **Tuberculous ulcers**\n‚Ä¢ **Vasculitic ulcers**\n\n**TECHNIQUE:**\n‚Ä¢ Take **3-4 biopsies** from **different edges** ‚≠ê\n‚Ä¢ **Wedge-shaped** (includes depth)\n‚Ä¢ **Avoid necrotic slough** (base of ulcer)\n‚Ä¢ Include **viable tissue** at edge\n\n**SPECIFIC ULCER TYPES:**\n\n**Marjolin's ulcer:**\n‚Ä¢ **Malignant transformation** in chronic wounds (burns, osteomyelitis)\n‚Ä¢ **SCC** most common\n‚Ä¢ Edge biopsy shows **malignant cells at margin**\n\n**Tuberculous ulcer:**\n‚Ä¢ Edge shows **epithelioid granulomas**\n‚Ä¢ **AFB staining** positive\n\nüí° **KEY:** **Chronic ulcer = Edge biopsy (normal-abnormal junction, multiple sites)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-11",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "How does skin graft derive its nutrition on day 3?",
    options: [
      "Plasma imbibition",
      "Inoculation",
      "Neovascularization",
      "None"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Inoculation (Option B)**\n\nüî¨ **SKIN GRAFT NUTRITION TIMELINE:**\n\n**PHASE 1: PLASMATIC IMBIBITION** (Day 0-2) ‚≠ê:\n‚Ä¢ **Passive diffusion** of plasma from wound bed\n‚Ä¢ Graft absorbs **plasma** like a sponge\n‚Ä¢ **No vascular connection** yet\n‚Ä¢ Graft becomes **edematous** (weight increases 40%)\n‚Ä¢ **Fibrin adhesion** attaches graft to bed\n\n**PHASE 2: INOSCULATION/INOCULATION** ‚≠ê‚≠ê‚≠ê **(Day 3-5 - THIS CASE)**:\n‚Ä¢ **Anastomosis** between graft vessels and recipient vessels\n‚Ä¢ **Pre-existing vessels** in graft connect to bed vessels\n‚Ä¢ **Direct vascular continuity** established ‚≠ê\n‚Ä¢ Most important phase for graft survival\n\n**PHASE 3: NEOVASCULARIZATION** (Day 5 onwards):\n‚Ä¢ **New capillaries** grow from recipient bed into graft\n‚Ä¢ **Angiogenesis** from wound bed\n‚Ä¢ **Complete revascularization** by day 7-10\n‚Ä¢ **Mature vascular network** established\n\n**AT DAY 3 SPECIFICALLY:**\n‚Ä¢ **Inoculation is dominant** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Graft vessels **link up** with bed vessels\n‚Ä¢ Blood flow **begins**\n‚Ä¢ **Critical period** - graft becomes pink\n\n**FACTORS FOR SUCCESSFUL GRAFT TAKE:**\n‚Ä¢ **Good recipient bed** (well-vascularized)\n‚Ä¢ **Immobilization** (prevent shearing)\n‚Ä¢ **No hematoma/seroma**\n‚Ä¢ **No infection**\n‚Ä¢ **Good contact** (tie-over dressing)\n\n**GRAFT FAILURE CAUSES:**\n‚Ä¢ **Hematoma** (most common) ‚≠ê\n‚Ä¢ **Infection**\n‚Ä¢ **Movement** (shearing forces)\n‚Ä¢ **Poor recipient bed** (avascular - bone, tendon)\n\nüí° **KEY:** **Day 3 = Inoculation (vessel-to-vessel anastomosis)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-12",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the ulcer",
    options: [
      "Arterial",
      "Venous",
      "Trophic",
      "Diabetic foot ulcer"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Venous ulcer (Option B)**\n\nüî¨ **VENOUS ULCERS:**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Venous insufficiency** ‚Üí **Venous hypertension** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Valve incompetence** (deep/superficial veins)\n‚Ä¢ **Chronic venous stasis**\n‚Ä¢ **Fibrin cuff formation** ‚Üí Impaired O‚ÇÇ diffusion\n‚Ä¢ **Tissue hypoxia** ‚Üí Ulceration\n\n**CHARACTERISTIC FEATURES:**\n\n**Location:** **Medial malleolus** (gaiter area) ‚≠ê‚≠ê‚≠ê **(MOST COMMON)**\n\n**Appearance:**\n‚Ä¢ **Shallow**, **irregular margins** ‚≠ê\n‚Ä¢ **Sloping edges** (not punched out)\n‚Ä¢ **Granulation tissue** at base\n‚Ä¢ **Serous exudate**\n\n**Surrounding skin:**\n‚Ä¢ **Hemosiderin pigmentation** (brown staining) ‚≠ê\n‚Ä¢ **Lipodermatosclerosis** (woody induration)\n‚Ä¢ **Inverted champagne bottle leg** appearance\n‚Ä¢ **Varicose eczema**\n‚Ä¢ **Atrophie blanche** (white scars)\n\n**Clinical:**\n‚Ä¢ **Moderate/dull pain** ‚≠ê (relieved by elevation)\n‚Ä¢ **Worse at end of day**\n‚Ä¢ **Varicose veins** present ‚≠ê\n‚Ä¢ **Pedal pulses present** (unlike arterial)\n\n**VS ARTERIAL ULCERS:**\n| Feature | Venous | Arterial |\n|---------|--------|----------|\n| Location | Medial malleolus | Pressure points (toes, heel) |\n| Edge | Irregular, sloping | Punched out |\n| Base | Granulation | Slough/necrotic |\n| Pain | Moderate (‚Üì elevation) | Severe (‚Üë elevation) |\n| Pulses | Present | Absent |\n\n**INVESTIGATIONS:**\n‚Ä¢ **Doppler USG** (assess venous insufficiency)\n‚Ä¢ **ABPI:** >0.8 (normal arterial supply)\n\n**MANAGEMENT:**\n\n**Conservative (Mainstay):**\n‚Ä¢ **Compression therapy** ‚≠ê‚≠ê‚≠ê **(GOLD STANDARD)**\n  - **4-layer bandage** or **compression stockings**\n  - **Contraindicated** if ABPI <0.8\n‚Ä¢ **Leg elevation** (above heart level)\n‚Ä¢ **Wound care** (dressings)\n‚Ä¢ **Antibiotics** (if infected)\n\n**Surgical:**\n‚Ä¢ Treat **varicose veins** (if present)\n‚Ä¢ **Skin grafting** (for large ulcers)\n\nüí° **KEY:** **Medial malleolus + Hemosiderin + Varicose veins = Venous ulcer ‚Üí Compression** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-13",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "A 30 year old female presented with the swelling in neck, what is the next step in evaluation?",
    options: [
      "I-131 scan",
      "FNAC",
      "TSH & T4",
      "FSH"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **TSH & T4 (Option C)**\n\nüî¨ **EVALUATION OF THYROID SWELLING:**\n\n**STEP-BY-STEP APPROACH:**\n\n**STEP 1: CLINICAL EXAMINATION** ‚≠ê\n‚Ä¢ **Inspection:** Size, symmetry, movement with swallowing\n‚Ä¢ **Palpation:** Consistency, nodularity, mobility\n‚Ä¢ **Assess function:** Signs of hyper/hypothyroidism\n‚Ä¢ **Regional lymph nodes**\n\n**STEP 2: THYROID FUNCTION TESTS** ‚≠ê‚≠ê‚≠ê **(FIRST INVESTIGATION - THIS CASE)**\n‚Ä¢ **TSH** (most sensitive) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Free T4** (& Free T3 if needed)\n\n**WHY TSH & T4 FIRST:**\n‚Ä¢ **Determines functional status** (euthyroid/hyper/hypo)\n‚Ä¢ **Guides further management**\n‚Ä¢ **Non-invasive**, **readily available**\n‚Ä¢ **Cost-effective**\n\n**INTERPRETATION:**\n‚Ä¢ **TSH ‚Üì, T4 ‚Üë:** **Hyperthyroidism** (Graves', toxic nodule)\n‚Ä¢ **TSH ‚Üë, T4 ‚Üì:** **Hypothyroidism** (Hashimoto's)\n‚Ä¢ **TSH normal, T4 normal:** **Euthyroid** (simple goiter, nodule)\n\n**STEP 3: IMAGING**\n‚Ä¢ **Ultrasound neck** ‚≠ê (first-line imaging)\n  - Characterize nodule (solid/cystic)\n  - Size, number, suspicious features\n  - Lymph nodes\n\n**STEP 4: FNAC** (if indicated) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Indications:**\n  - **Suspicious USG features** (hypoechoic, microcalcifications, irregular margins)\n  - **Nodule >1cm**\n  - **Family history** of thyroid cancer\n  - **Rapid growth**\n  - **Hard, fixed nodule**\n\n**STEP 5: THYROID SCAN** (I-131 or Tc-99m)\n‚Ä¢ **NOT first-line** ‚≠ê\n‚Ä¢ **Indications:**\n  - **Hyperthyroidism** (identify hot/cold nodules)\n  - **Toxic adenoma** vs **Graves' disease**\n\n**CORRECT SEQUENCE:**\n1. **Clinical examination**\n2. **TSH & T4** ‚úÖ **(FIRST LAB TEST)**\n3. **USG neck**\n4. **FNAC** (if suspicious)\n5. **Thyroid scan** (if hyperthyroid)\n\nüí° **KEY:** **Any thyroid swelling ‚Üí First test = TSH & T4** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },{
    id: "neet-pg-2024-shift2-14",
    subjectId: "surgery",
    chapterId: "neet-pg-2024",
    question: "Identify the drain in the image",
    options: [
      "Romovac drain",
      "Jackson-Pratt drain",
      "Corrugated drain",
      "Penrose drain"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Romovac drain (Option A)**\n\nüî¨ **SURGICAL DRAINS CLASSIFICATION:**\n\n**ROMOVAC DRAIN** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**:\n\n**TYPE:** **Closed suction drain** with **portable suction reservoir**\n\n**COMPONENTS:**\n‚Ä¢ **Perforated tube**\n‚Ä¢ **Suction bulb/bottle** (creates negative pressure)\n‚Ä¢ **Closed collection system**\n\n**MECHANISM:**\n‚Ä¢ **Constant low negative pressure** (by compressing bulb)\n‚Ä¢ **Active drainage**\n‚Ä¢ **Prevents fluid accumulation**\n\n**ADVANTAGES:**\n‚Ä¢ **Quantifiable drainage** ‚≠ê (measure output)\n‚Ä¢ **Reduced infection risk** (closed system)\n‚Ä¢ **Patient mobility** (portable)\n‚Ä¢ **Effective** for large volumes\n\n**INDICATIONS:**\n‚Ä¢ **Mastectomy** ‚≠ê\n‚Ä¢ **Thyroidectomy**\n‚Ä¢ **Orthopedic surgeries** (joint replacements)\n‚Ä¢ **Plastic surgery**\n‚Ä¢ **Neck dissections**\n\n**COMPARISON OF DRAINS:**\n\n**CLOSED DRAINS (Active):**\n\n**1. Romovac:**\n‚Ä¢ **Bottle** reservoir (larger capacity)\n‚Ä¢ High-volume drainage\n\n**2. Jackson-Pratt (JP):**\n‚Ä¢ **Bulb** reservoir (smaller)\n‚Ä¢ Similar to Romovac, more portable\n‚Ä¢ \"Grenade-shaped\" bulb\n\n**OPEN DRAINS (Passive):**\n\n**3. Penrose drain:**\n‚Ä¢ **Soft rubber tube**\n‚Ä¢ **Flat** when empty\n‚Ä¢ **Passive drainage** (gravity/capillary)\n‚Ä¢ **Higher infection risk**\n‚Ä¢ Used in **abscess cavities**\n\n**4. Corrugated drain:**\n‚Ä¢ **Rigid**, **corrugated rubber**\n‚Ä¢ **Open system**\n‚Ä¢ Drains by **capillary action**\n‚Ä¢ Rarely used now\n\n**KEY DIFFERENCES:**\n| Feature | Romovac/JP | Penrose | Corrugated |\n|---------|-----------|---------|------------|\n| System | Closed | Open | Open |\n| Mechanism | Active suction | Passive | Passive |\n| Infection risk | Low | High | High |\n| Quantification | Yes | No | No |\n| Indication | Clean surgeries | Abscesses | Obsolete |\n\n**REMOVAL CRITERIA:**\n‚Ä¢ **Drainage <30-50 mL/24 hours** ‚≠ê\n‚Ä¢ **Non-purulent**\n‚Ä¢ **No active bleeding**\n\nüí° **KEY:** **Closed suction with bulb/bottle = Romovac/JP drain** ‚≠ê‚≠ê‚≠ê",
    difficulty: "easy",
    year: 2024
  },{
    id: "neet-pg-2023-39",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 55-year-old male presented with verrucous carcinoma around the glans of the penis. Examination reveals that the inguinal lymph nodes are not enlarged. What is the appropriate management for this patient?",
    options: [
      "Total penectomy",
      "CO2 laser excision",
      "Topical 5-fluorouracil",
      "Partial penectomy d",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Partial penectomy (Option D)**\n\nüî¨ **PENILE VERRUCOUS CARCINOMA:**\n\n**TYPE:** Low-grade **squamous cell carcinoma** variant ‚≠ê\n‚Ä¢ **Locally invasive**, rarely metastasizes\n\n**MANAGEMENT:**\n‚Ä¢ **Partial penectomy** ‚≠ê‚≠ê‚≠ê (with **2cm margin**)\n‚Ä¢ **Preserve** as much penis as possible\n‚Ä¢ **NO lymph node dissection** (if nodes not enlarged)\n\n**INDICATIONS FOR TOTAL:**\n‚Ä¢ Lesion involves >50% of shaft\n‚Ä¢ Invasion of corpora\n\nüí° **KEY:** **Localized penile cancer + No nodes = Partial penectomy** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-40",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "Identify the procedure being performed in the image given below. p e r P",
    options: [
      "Intraosseous cannula for pain relief",
      "Bone marrow aspiration",
      "Intraosseous route access for giving IV fluids",
      "Intraosseous abscess drainage",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Intraosseous route access for giving IV fluids (Option C)**\n\nüî¨ **INTRAOSSEOUS (IO) ACCESS:**\n\n**INDICATION:** **Emergency vascular access** when IV difficult ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Shock**, **cardiac arrest**\n‚Ä¢ **Failed IV attempts** (children)\n\n**SITE:**\n‚Ä¢ **Proximal tibia** (most common) ‚≠ê\n‚Ä¢ Distal femur, distal tibia\n\n**CAN GIVE:**\n‚Ä¢ **IV fluids** ‚≠ê\n‚Ä¢ **Medications** (same as IV)\n‚Ä¢ **Blood products**\n\n**ADVANTAGES:** Fast, reliable, works in shock\n\nüí° **KEY:** **IO access = Emergency IV route via bone marrow** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-41",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A diabetic patient presents with sudden-onset perineal pain. On examinatiorn, foul-smelling discharge, and necrotic tissue as seen in the image is noted. Which of the following is true about the given condition? e d d a L",
    options: [
      "Anti-gas gangrene serum indicated for all cases",
      "Urinary diversion is the next ste e",
      "Bilateral orchidectomy must be done",
      "Mixed aerobic and anaerobic infection P",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Mixed aerobic and anaerobic infection (Option D)**\n\nüî¨ **FOURNIER'S GANGRENE:**\n\n**DEFINITION:** **Necrotizing fasciitis** of **perineum/genitalia** ‚≠ê‚≠ê‚≠ê\n\n**MICROBIOLOGY:** **Polymicrobial** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Mixed aerobic + anaerobic** bacteria\n‚Ä¢ E. coli, Bacteroides, Streptococcus, Staphylococcus\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Diabetic** patient ‚≠ê (risk factor)\n‚Ä¢ **Sudden perineal pain** ‚≠ê\n‚Ä¢ **Foul-smelling discharge**\n‚Ä¢ **Necrotic tissue**\n‚Ä¢ **Crepitus** (gas)\n\n**MANAGEMENT:**\n‚Ä¢ **Emergency surgical debridement** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Broad-spectrum antibiotics** (aerobic + anaerobic coverage)\n‚Ä¢ **Supportive care** (fluids, glucose control)\n\n**NOT INDICATED:**\n‚Ä¢ Anti-gas gangrene serum (for Clostridium)\n‚Ä¢ Orchidectomy (preserve viable tissue)\n\nüí° **KEY:** **Fournier's = Mixed infection ‚Üí Emergency debridement** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-42",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "Which of the following is the most common complication following ligation of the first vessel during abdominoperineal resection for rectal carcinoma? (APR Abdominoperineal resection)",
    options: [
      "Parasympathetic-bladder dysfunction and retrograde ejaculation.",
      "Sympathetic - - bladder dysfunction and impotence.",
      "Sympathetic- retrograde ejaculation and bladder dysfunction.",
      "Sympathetic-Impotence and loss of cutaneous sensation in perineal region",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Sympathetic - retrograde ejaculation and bladder dysfunction (Option C)**\n\nüî¨ **APR COMPLICATIONS:**\n\n**FIRST VESSEL LIGATED:** **Inferior mesenteric artery (IMA)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Runs with **superior hypogastric plexus** (sympathetic)\n\n**INJURY TO SYMPATHETIC PLEXUS:**\n\n**1. Retrograde ejaculation** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Loss of **bladder neck closure** during ejaculation\n‚Ä¢ Semen goes into bladder\n\n**2. Bladder dysfunction** ‚≠ê\n‚Ä¢ **Neurogenic bladder**\n‚Ä¢ Urinary retention\n\n**PARASYMPATHETIC INJURY:**\n‚Ä¢ **Impotence** (from pelvic plexus injury)\n\nüí° **KEY:** **APR ‚Üí Sympathetic injury ‚Üí Retrograde ejaculation + Bladder dysfunction** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page20_img10.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-43",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presents to the clinic with the lesion given in the image. He had a traumatic injury to d the chest one year ago. What is the most likely diagnosis? d a L p e",
    options: [
      "Hemangioma",
      "Hypertrophic sca P",
      "Keloid",
      "Neurofibroma",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Keloid (Option C)**\n\nüî¨ **KELOID vs HYPERTROPHIC SCAR:**\n\n**KELOID** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Extends beyond original wound** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Does NOT regress** over time\n‚Ä¢ **Chest** (common site) ‚≠ê\n‚Ä¢ **1 year post-trauma** (this case)\n‚Ä¢ More common in **dark skin**\n\n**HYPERTROPHIC SCAR:**\n‚Ä¢ **Within wound boundaries**\n‚Ä¢ **May regress** over 1-2 years\n\n**TREATMENT:**\n‚Ä¢ **Intralesional steroids** (triamcinolone)\n‚Ä¢ **Silicone gel sheets**\n‚Ä¢ **Pressure garments**\n\nüí° **KEY:** **Extends beyond wound + Chest = Keloid** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-44",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 45-year-old male underwent bilateral laparoscopic hernia repair for inguinal hernia. Postoperatively, he complained of pain in the right thigh. Which of the following nerve entrapment leads to this symptom?",
    options: [
      "Ilioinguinal nerve",
      "Iliohypogastric nerve",
      "Femoral nerv r",
      "Lateral cutaneous nerve of thigh e",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Lateral cutaneous nerve of thigh (Option D)**\n\nüî¨ **MERALGIA PARESTHETICA:**\n\n**NERVE:** **Lateral femoral cutaneous nerve** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Purely **sensory**\n‚Ä¢ Innervates **lateral thigh**\n\n**CAUSE (POST-HERNIA REPAIR):**\n‚Ä¢ **Entrapment** during mesh fixation ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Especially with **lateral placement** of tacks\n\n**CLINICAL:**\n‚Ä¢ **Pain**, **numbness**, **tingling** in **anterolateral thigh** ‚≠ê\n‚Ä¢ **NO motor deficit**\n\n**PREVENTION:** Avoid fixation **lateral to anterior superior iliac spine (ASIS)**\n\nüí° **KEY:** **Post-hernia repair + Thigh pain = Lateral cutaneous nerve entrapment** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page21_img11.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-45",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient was brought to the ER following a road traffic accident. On examination, the patient opens his eyes to a painful stimulus, speaaks inappropriately, and withdraws his limbs to a painful stimulus. What is his GCS score?",
    options: [
      "E2V2M3",
      "E3V3M3",
      "E2V3M4 e",
      "E3V2M2",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **E2V3M4 (Option C)**\n\nüî¨ **GLASGOW COMA SCALE (GCS):**\n\n**THIS PATIENT:**\n\n**Eye (E):**\n‚Ä¢ **Opens to pain** = **E2** ‚≠ê\n\n**Verbal (V):**\n‚Ä¢ **Inappropriate words** = **V3** ‚≠ê\n\n**Motor (M):**\n‚Ä¢ **Withdraws to pain** (flexion withdrawal) = **M4** ‚≠ê\n\n**TOTAL:** **E2 + V3 + M4 = 9/15**\n\n**GCS INTERPRETATION:**\n‚Ä¢ **13-15:** Mild TBI\n‚Ä¢ **9-12:** Moderate TBI ‚≠ê (this case)\n‚Ä¢ **‚â§8:** Severe TBI (intubate)\n\nüí° **KEY:** **E2V3M4 = GCS 9 (Moderate TBI)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-46",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presented with fever and abdominal pain with jaundice. Investigations showed the given findings. Which of the following statements is true regarding this condition?",
    options: [
      "Surgery is mandatory",
      "Fine-needle aspiration cytology is diagnostic",
      "Angioembolization is the treatment of choice",
      "Echinococcus species is involved in etiology d",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Echinococcus species is involved in etiology (Option D)**\n\nüî¨ **HYDATID CYST OF LIVER:**\n\n**ORGANISM:** **Echinococcus granulosus** ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **Fever**, **jaundice** (if ruptured/infected)\n‚Ä¢ **RUQ pain**\n‚Ä¢ **Hepatomegaly**\n\n**IMAGING:** **Cystic lesions** with **daughter cysts** ‚≠ê\n\n**KEY FACTS:**\n\n**FNAC CONTRAINDICATED** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ Risk of **anaphylaxis**\n‚Ä¢ Risk of **peritoneal dissemination**\n\n**DIAGNOSIS:**\n‚Ä¢ **Serology** (Echinococcus IgG)\n‚Ä¢ **Imaging** (USG/CT)\n\n**TREATMENT:**\n‚Ä¢ **Surgery** (pericystectomy/cystectomy) ‚≠ê\n‚Ä¢ **Albendazole** (pre/post-op)\n\nüí° **KEY:** **Hydatid cyst ‚Üí Echinococcus + NEVER do FNAC** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page22_img12.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-47",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient who is a known case of alcohol dependence syndrome presents with sudden and p unintentional weight loss. What is the most likely diagnosis? -ALP 240 IU/L -S. Direct bilirubin - 1 mg/dL e -AST/ALT -0.5 -Alpha fetoprotein- 600 ng/mL",
    options: [
      "Hepatic adenom OP2: Cholangiocarcinom O 3: Hepatocellular carcinom O4: Alcoholic hepatitis",
      "Option 2",
      "Option 3",
      "Alcoholic hepatitis",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Hepatocellular carcinoma (Option C)**\n\nüî¨ **HEPATOCELLULAR CARCINOMA (HCC):**\n\n**RISK FACTOR:** **Chronic alcohol** ‚≠ê (cirrhosis)\n\n**CLINICAL:**\n‚Ä¢ **Weight loss** ‚≠ê\n‚Ä¢ **RUQ pain**\n‚Ä¢ **Jaundice**\n\n**KEY LAB (THIS CASE):**\n‚Ä¢ **Alpha-fetoprotein (AFP) >400 ng/mL** ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC)**\n  - Normal: <10 ng/mL\n  - >400 = **highly suggestive of HCC**\n‚Ä¢ **AST/ALT ratio <0.5** (unusual, but ALT may be very high)\n‚Ä¢ **ALP elevated** (cholestasis)\n\n**DIAGNOSIS:**\n‚Ä¢ **AFP + Imaging** (triphasic CT/MRI)\n‚Ä¢ **Biopsy** if uncertain\n\n**TREATMENT:**\n‚Ä¢ **Resection/transplant** (curative)\n‚Ä¢ **TACE, sorafenib** (palliative)\n\nüí° **KEY:** **Alcoholic + Weight loss + AFP >400 = HCC** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-51",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presented with features of chronic pancreatitis with recurrent attacks and has a 10 mm dilatation of the pancreatic duct with intraductal calculi present. Which of the following is the surgery of choice?",
    options: [
      "Pancreaticoduodenectomy",
      "Longitudinal pancreaticojejunostomy",
      "ERCP and sphincterotomy",
      "Coring of pancreas hea d",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Longitudinal pancreaticojejunostomy (Puestow procedure) (Option B)**\n\nüî¨ **CHRONIC PANCREATITIS - SURGICAL MANAGEMENT:**\n\n**INDICATION FOR SURGERY:**\n‚Ä¢ **Intractable pain** ‚≠ê\n‚Ä¢ **Recurrent attacks**\n\n**THIS CASE:**\n‚Ä¢ **Dilated duct (>10mm)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Intraductal calculi** ‚≠ê\n\n**SURGERY OF CHOICE:** **Lateral pancreaticojejunostomy (Puestow procedure)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Split duct longitudinally**\n‚Ä¢ **Anastomose** to jejunum (Roux-en-Y)\n‚Ä¢ **Best pain relief** for dilated duct\n\n**OTHER PROCEDURES:**\n‚Ä¢ **Whipple** (mass in head)\n‚Ä¢ **Frey** (duct dilation + head mass)\n\nüí° **KEY:** **Dilated duct (>7mm) + Calculi = Lateral pancreaticojejunostomy (Puestow)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-56",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "d A woman presented with a BIRADS-5 breast lesion. Which of the following is a good prognostic factor for this lesion? a",
    options: [
      "BRCA-1 positive",
      "p53 positive",
      "ER positive",
      "High Ki-67 e",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **ER positive (Option C)**\n\nüî¨ **BREAST CANCER PROGNOSTIC FACTORS:**\n\n**BIRADS-5:** **Highly suspicious for malignancy** (>95% cancer)\n\n**GOOD PROGNOSTIC FACTORS:**\n‚Ä¢ **ER/PR positive** ‚≠ê‚≠ê‚≠ê (hormone receptor positive)\n‚Ä¢ **HER2 negative**\n‚Ä¢ **Low grade**\n‚Ä¢ **Low Ki-67** (<14%)\n‚Ä¢ **Small tumor** (<2cm)\n‚Ä¢ **Node negative**\n\n**POOR PROGNOSTIC FACTORS:**\n‚Ä¢ **BRCA-1 positive** ‚≠ê (triple negative, aggressive)\n‚Ä¢ **p53 mutation** ‚≠ê (aggressive)\n‚Ä¢ **High Ki-67** ‚≠ê (high proliferation)\n‚Ä¢ **HER2 positive**\n\n**ER POSITIVE:**\n‚Ä¢ **Better prognosis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Responds to hormonal therapy** (tamoxifen, aromatase inhibitors)\n\nüí° **KEY:** **ER positive = Good prognosis in breast cancer** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-58",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presents with sudden onset of chest pain shooting to the neck and interscapular region. X-ray shows widened mediastinum. BP is 110/90 mmHg in the right upper limb and 160/100 mmHg in the left upper limb. What is the most likely diagnosis?",
    options: [
      "Acute coronary syndrome",
      "Acute pulmonary embolism",
      "Acute aortic dissection",
      "Esophageal rupture",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Acute aortic dissection (Option C)**\n\nüî¨ **AORTIC DISSECTION:**\n\n**CLASSIC TRIAD** ‚≠ê‚≠ê‚≠ê:\n1. **Tearing chest pain** ‚Üí **Back/interscapular** ‚≠ê‚≠ê‚≠ê\n2. **Widened mediastinum** on CXR ‚≠ê\n3. **Pulse/BP differential** between limbs ‚≠ê‚≠ê‚≠ê (>20 mmHg)\n\n**THIS CASE:**\n‚Ä¢ **Right arm:** 110/90 mmHg\n‚Ä¢ **Left arm:** 160/100 mmHg\n‚Ä¢ **Difference:** 50 mmHg (dissection involving left subclavian)\n\n**CLASSIFICATION:**\n‚Ä¢ **Stanford A:** Ascending aorta ‚≠ê (surgical emergency)\n‚Ä¢ **Stanford B:** Descending aorta (medical management)\n\n**DIAGNOSIS:** **CT angiography** ‚≠ê‚≠ê‚≠ê (gold standard)\n\n**TREATMENT:**\n‚Ä¢ **Type A:** **Emergency surgery** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Type B:** **Medical** (Œ≤-blockers, control BP)\n\nüí° **KEY:** **Tearing pain + Widened mediastinum + BP differential = Aortic dissection** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page28_img16.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-60",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presented with right hypochondriac pain. He had an episode of diarrhea 1 week e prior. CT scan of the abdomen reveals a liver abscess of around 25 ccs. What is the next step in management? r",
    options: [
      "PAIR P",
      "S urgery",
      "Medical therapy",
      "Percutaneous drainage",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Medical therapy (Option C)**\n\nüî¨ **AMOEBIC LIVER ABSCESS MANAGEMENT:**\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **RUQ pain**\n‚Ä¢ **History of diarrhea** ‚≠ê (amoebiasis)\n‚Ä¢ **Abscess <5 cm** (25 cc ‚âà 3 cm) ‚≠ê‚≠ê‚≠ê\n\n**SIZE-BASED MANAGEMENT:**\n\n**<5 cm:** **Medical therapy alone** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Metronidazole** 750 mg TID √ó 7-10 days\n‚Ä¢ **Followed by paromomycin** (luminal agent)\n\n**5-10 cm:**\n‚Ä¢ **Medical + Aspiration** (if no response in 3-5 days)\n\n**>10 cm or complicated:**\n‚Ä¢ **Percutaneous drainage**\n‚Ä¢ Left lobe, impending rupture\n\n**SURGERY:** Rarely needed (rupture, failed drainage)\n\nüí° **KEY:** **Small amoebic abscess (<5 cm) = Medical therapy (Metronidazole)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page29_img17.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-62",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 50-year-old patient with a history of trauma one week back presents with confusion and ataxia. He is on treatment for alcohol dependence and his last intake was 2 weeks back. CT scan reveals the following finding. What is the diagnosis? r e d d a L p",
    options: [
      "Extradural hemorrhag e",
      "Subdural hemorrhage",
      "Intra-parenchymal hemorrhag P",
      "Subarachnoid hemorrhage",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Subdural hemorrhage (SDH) (Option B)**\n\nüî¨ **CHRONIC SUBDURAL HEMATOMA:**\n\n**RISK FACTORS (THIS CASE):**\n‚Ä¢ **Chronic alcoholism** ‚≠ê‚≠ê‚≠ê (brain atrophy)\n‚Ä¢ **Trauma 1 week ago** ‚≠ê\n‚Ä¢ **Elderly**\n\n**CLINICAL:**\n‚Ä¢ **Confusion**, **ataxia** ‚≠ê\n‚Ä¢ **Delayed presentation** (days-weeks post-trauma)\n‚Ä¢ Fluctuating symptoms\n\n**CT FINDINGS:**\n‚Ä¢ **Crescentic** (follows brain contour) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hypodense** (chronic) or mixed density\n‚Ä¢ **Crosses suture lines**, does NOT cross midline\n‚Ä¢ **Mass effect** (midline shift)\n\n**VS EDH:**\n‚Ä¢ **Lens-shaped** (biconvex)\n‚Ä¢ **Does NOT cross sutures**\n‚Ä¢ **Acute presentation**\n\n**TREATMENT:** **Burr hole drainage** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **Alcoholic + Delayed trauma + Crescentic lesion = Chronic SDH** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-63",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "Which of the following is false about the given condition?",
    options: [
      "Repeated radical surgery every 24 hours may be required to adequately manage this condition a",
      "This is a case of Meleney's gangrene",
      "The condition is caused by Œ≤ hemolytic streptococcus and may sometimes be polymicrobial",
      "Hyperbaric oxygen has npo role in the treatment of this condition",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Hyperbaric oxygen has NO role - FALSE (Option D)**\n\nüî¨ **NECROTIZING FASCIITIS (Meleney's Gangrene):**\n\n**THIS IS FALSE:** Hyperbaric oxygen **DOES have a role** ‚≠ê‚≠ê‚≠ê (as adjunct therapy)\n\n**TRUE STATEMENTS:**\n\n**A. Repeated debridement** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Every 24-48 hours** until clean\n‚Ä¢ **Aggressive surgical debridement** is mainstay\n\n**B. Meleney's gangrene:**\n‚Ä¢ Type of **synergistic gangrene**\n‚Ä¢ **Necrotizing soft tissue infection**\n\n**C. Organisms:**\n‚Ä¢ **Œ≤-hemolytic Streptococcus** (Group A) ‚≠ê\n‚Ä¢ Often **polymicrobial** ‚≠ê (with anaerobes)\n\n**TREATMENT:**\n‚Ä¢ **Surgical debridement** ‚≠ê‚≠ê‚≠ê (primary)\n‚Ä¢ **Broad-spectrum antibiotics**\n‚Ä¢ **Hyperbaric oxygen** ‚≠ê (adjunct - improves oxygen delivery, bactericidal)\n\nüí° **KEY:** **HBO IS used in necrotizing fasciitis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-65",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presents with a swelling in the groin region and it is diagnosed as a direct inguinal hernia. Weakness in which of the following structures is most likely to cause this condition?",
    options: [
      "Pectineal ligament r",
      "Conjoint tendon e",
      "Reflected part of inguinal ligament d",
      "Lacunar ligament",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Conjoint tendon (Option B)**\n\nüî¨ **DIRECT INGUINAL HERNIA:**\n\n**ANATOMY:**\n‚Ä¢ **Hernia sac protrudes** through **Hesselbach's triangle** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **MEDIAL** to inferior epigastric vessels\n\n**WEAKNESS IN:** **Transversalis fascia + Conjoint tendon** ‚≠ê‚≠ê‚≠ê\n\n**CONJOINT TENDON:**\n‚Ä¢ Formed by **internal oblique + transversus abdominis** aponeuroses\n‚Ä¢ Forms **MEDIAL wall** of inguinal canal\n‚Ä¢ **Weakness** ‚Üí **Direct hernia**\n\n**HESSELBACH'S TRIANGLE:**\n‚Ä¢ **Medial:** Rectus abdominis (lateral edge)\n‚Ä¢ **Lateral:** Inferior epigastric vessels ‚≠ê\n‚Ä¢ **Inferior:** Inguinal ligament\n\n**VS INDIRECT:**\n‚Ä¢ **Indirect:** Through **deep ring**, lateral to epigastric vessels\n‚Ä¢ **Direct:** Through **Hesselbach's**, medial to epigastric vessels\n\nüí° **KEY:** **Direct hernia = Weakness of conjoint tendon** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-70",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "Question 70 - [Content needs manual review]",
    options: [
      "Option 1",
      "Exposure to thinners and paints",
      "Continuous exposure to cement and concrete",
      "Continuous exposure to drills and machines",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Continuous exposure to drills and machines (Option D)**\n\nüî¨ **HAND-ARM VIBRATION SYNDROME (HAVS):**\n\n**IMAGE (LIKELY):** Shows **Raynaud's phenomenon** or **finger blanching** ‚≠ê\n\n**CAUSE:** **Vibrating tools** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Drills**, **jackhammers**, **chainsaws**\n‚Ä¢ **Prolonged exposure** (months-years)\n\n**CLINICAL:**\n‚Ä¢ **Raynaud's phenomenon** (white ‚Üí blue ‚Üí red fingers) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Numbness**, **tingling**\n‚Ä¢ **Reduced grip strength**\n‚Ä¢ **Pain**\n\n**MECHANISM:**\n‚Ä¢ **Vascular damage** (vasoconstriction)\n‚Ä¢ **Nerve damage** (vibration neuropathy)\n\n**MANAGEMENT:**\n‚Ä¢ **Avoid vibrating tools** ‚≠ê\n‚Ä¢ **Keep hands warm**\n‚Ä¢ **Calcium channel blockers** (if severe)\n\nüí° **KEY:** **Raynaud's + Vibrating tools = HAVS** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page34_img20.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-72",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 5-year-old child was admitted tLo the hospital for prolapsing rectal mass and painless rectal bleeding. Histopathological examination reveals enlarged and inflamed glands filled with mucin. What is the likely diagnosis? p",
    options: [
      "Adenom e",
      "Choristoma",
      "Hamartom OP4: Carcinom A ns: 3",
      "Option 4",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Hamartoma (Juvenile Polyp) (Option C)**\n\nüî¨ **JUVENILE POLYP:**\n\n**AGE:** **Children** (2-10 years) ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Prolapsing rectal mass** ‚≠ê\n‚Ä¢ **Painless rectal bleeding** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Can autoamputate**\n\n**HISTOPATHOLOGY:**\n‚Ä¢ **Hamartoma** ‚≠ê‚≠ê‚≠ê (not neoplastic)\n‚Ä¢ **Enlarged, dilated glands** filled with **mucin** ‚≠ê\n‚Ä¢ **Inflamed stroma**\n‚Ä¢ **Cystic spaces**\n\n**LOCATION:** **Rectum** (most common) ‚≠ê\n\n**MANAGEMENT:**\n‚Ä¢ **Endoscopic polypectomy** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Usually solitary**\n‚Ä¢ **NO malignant potential** ‚≠ê\n\n**VS ADENOMA:**\n‚Ä¢ **Adenoma:** Neoplastic, adults, malignant potential\n\nüí° **KEY:** **Child + Rectal bleeding + Mucin-filled glands = Juvenile polyp (Hamartoma)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page35_img21.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-75",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "r Identify the given condition. P",
    options: [
      "Venous ulcer",
      "Malignant ulcer",
      "Arterial ulcer",
      "Trophic ulcer",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Trophic ulcer (Option D)**\n\nüî¨ **TROPHIC ULCER (Neuropathic Ulcer):**\n\n**CAUSE:** **Loss of sensation** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Diabetes** (peripheral neuropathy) ‚≠ê\n‚Ä¢ **Leprosy**\n‚Ä¢ **Spinal cord injury**\n\n**LOCATION:** **Pressure points** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Sole of foot** (heel, metatarsal heads) ‚≠ê\n‚Ä¢ Areas of **repetitive trauma**\n\n**CLINICAL:**\n‚Ä¢ **Painless** ‚≠ê‚≠ê‚≠ê (due to neuropathy)\n‚Ä¢ **Punched-out appearance**\n‚Ä¢ **Deep**, **well-defined margins**\n‚Ä¢ **Callused edges**\n‚Ä¢ **Clean base** or infected\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Repeated trauma** (no pain sensation)\n‚Ä¢ **Poor healing** (neuropathy + vascular disease)\n\n**MANAGEMENT:**\n‚Ä¢ **Pressure offloading** ‚≠ê (special footwear)\n‚Ä¢ **Wound care**\n‚Ä¢ **Treat underlying cause**\n\nüí° **KEY:** **Painless ulcer on sole + Neuropathy = Trophic ulcer** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-85",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "e A patient comes to the casualty with a severe headache. His BP was found to be 160/100 mmHg. CT scan revealed a subarachnoid hemorrhage. What is the next best step in the management of this patient? d",
    options: [
      "Nimodipin d",
      "Angiography",
      "Surgery",
      "Fibrinolytic therapy L",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Angiography (Option B)**\n\nüî¨ **SUBARACHNOID HEMORRHAGE (SAH) MANAGEMENT:**\n\n**CONFIRMED SAH ON CT** ‚Üí **Next step:** **CT/DSA Angiography** ‚≠ê‚≠ê‚≠ê\n\n**PURPOSE:**\n‚Ä¢ **Identify source** (aneurysm, AVM) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Plan treatment** (coiling vs clipping)\n‚Ä¢ **Assess other aneurysms**\n\n**INITIAL MANAGEMENT (SIMULTANEOUS):**\n‚Ä¢ **Bed rest**, **analgesia**\n‚Ä¢ **Nimodipine** ‚≠ê‚≠ê‚≠ê (prevent vasospasm)\n  - **60 mg PO q4h √ó 21 days**\n  - **Reduces delayed cerebral ischemia**\n‚Ä¢ **BP control** (cautious - maintain perfusion)\n\n**DEFINITIVE TREATMENT (AFTER ANGIOGRAPHY):**\n‚Ä¢ **Endovascular coiling** ‚≠ê (preferred)\n‚Ä¢ **Surgical clipping**\n\n**NOT INDICATED:**\n‚Ä¢ **Fibrinolytics:** CONTRAINDICATED ‚≠ê (worsen bleeding)\n\nüí° **KEY:** **SAH confirmed ‚Üí Angiography (find aneurysm) + Nimodipine** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-88",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 20-year-old female patient consumed a cleaning product containing 90% sodium hydroxide. She is having complete dysphagia. What is the best step in management?",
    options: [
      "Esophagojejunostomy",
      "Stent placement",
      "Feeding jejunostomy",
      "Gastrojejunostomy",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Feeding jejunostomy (Option C)**\n\nüî¨ **CAUSTIC ESOPHAGEAL INJURY:**\n\n**AGENT:** **90% sodium hydroxide** (alkali) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Severe injury** (liquefactive necrosis)\n‚Ä¢ **Complete dysphagia** = severe stricture/perforation risk\n\n**ACUTE MANAGEMENT:**\n\n**1. NPO (nil per os)** ‚≠ê\n‚Ä¢ **NO oral intake**\n‚Ä¢ **NO NG tube** (risk of perforation)\n\n**2. Feeding jejunostomy** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Nutritional support** while esophagus heals\n‚Ä¢ **Temporary** (weeks-months)\n‚Ä¢ Allows **delayed reconstruction**\n\n**3. Endoscopy** (within 24 hours)\n‚Ä¢ **Assess severity**\n‚Ä¢ **No endoscopy if perforation suspected**\n\n**LATER (after acute phase):**\n‚Ä¢ **Esophageal reconstruction** (if stricture)\n‚Ä¢ **Colon interposition** or **gastric pull-up**\n\n**NOT INDICATED:**\n‚Ä¢ **Stent:** Risk of perforation/migration\n‚Ä¢ **Immediate surgery:** Unless perforation\n\nüí° **KEY:** **Caustic injury + Complete dysphagia ‚Üí Feeding jejunostomy (NPO)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-89",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "e A 23-year-old male patient presents with midline swelling in the neck. The swelling moves with deglutition and protrusion of the tongue. What is the likely diagnosis? d",
    options: [
      "Brachial cyst",
      "Thyroglossal cyst",
      "Plunging ranula a",
      "Dermoid cyst L",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Thyroglossal cyst (Option B)**\n\nüî¨ **THYROGLOSSAL CYST:**\n\n**CLASSIC FEATURES** ‚≠ê‚≠ê‚≠ê:\n1. **Midline neck swelling** ‚≠ê‚≠ê‚≠ê\n2. **Moves with swallowing** ‚≠ê‚≠ê‚≠ê (attached to hyoid)\n3. **Moves with tongue protrusion** ‚≠ê‚≠ê‚≠ê **(PATHOGNOMONIC)**\n\n**EMBRYOLOGY:**\n‚Ä¢ **Remnant of thyroglossal duct** ‚≠ê\n‚Ä¢ **Thyroid descends** from foramen cecum ‚Üí anterior neck\n‚Ä¢ **Duct normally obliterates**\n\n**LOCATION:** **Between hyoid bone and thyroid** ‚≠ê\n\n**TREATMENT:** **Sistrunk operation** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Excise cyst + middle 1/3 of hyoid bone** + duct\n\n**VS OTHER CYSTS:**\n‚Ä¢ **Branchial cyst:** **Lateral** neck, anterior to SCM\n‚Ä¢ **Dermoid:** Midline, does NOT move with swallowing/tongue\n‚Ä¢ **Ranula:** **Floor of mouth**\n\nüí° **KEY:** **Midline + Moves with swallowing + tongue = Thyroglossal cyst** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-91",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A young patient is admitted with a history of fever for 5 days. BP is 90/60 mmHg, PR-120 bpm, RR-24 breaths/ min, GCS score-10; laboratory tests show leucocytosis with neutrophilia and serum creatinine level of 2.6 mg/ dL. An intern doctor wants to calculate the qSOFA score to predict prognosis and hospitalization duration. Which of the following comprises the qSOFA score? r",
    options: [
      "BP, RR and CBC e",
      "Creatinine, PR, BP d",
      "RR, Body temperature, PR",
      "SBP, RR, GCS score",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **SBP, RR, GCS score (Option D)**\n\nüî¨ **qSOFA (Quick SOFA Score):**\n\n**CRITERIA** ‚≠ê‚≠ê‚≠ê **(3 parameters only)**:\n1. **Systolic BP ‚â§100 mmHg** ‚≠ê\n2. **Respiratory rate ‚â•22/min** ‚≠ê\n3. **Altered mental status (GCS <15)** ‚≠ê\n\n**SCORING:**\n‚Ä¢ **1 point** for each criterion\n‚Ä¢ **‚â•2 points** = **High risk** of poor outcome ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE:**\n‚Ä¢ **BP 90/60** ‚Üí SBP <100 ‚úì (1 point)\n‚Ä¢ **RR 24** ‚Üí ‚â•22 ‚úì (1 point)\n‚Ä¢ **GCS 10** ‚Üí <15 ‚úì (1 point)\n‚Ä¢ **Total: 3/3** = High risk\n\n**PURPOSE:** **Bedside screening** for sepsis (no labs needed) ‚≠ê\n\n**NOT INCLUDED:**\n‚Ä¢ Temperature, PR, CBC, creatinine\n\nüí° **KEY:** **qSOFA = SBP + RR + GCS (No labs!)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-1",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 54-year-old woman presents with cervical cancer stage 2A. It is decided to give neoadjuvant chemotherapy. What does neoadjuvant chemotherapy mean?",
    options: [
      "Chemotherapy is given along with radiation.",
      "Chemotherapy is given during surgery.",
      "Chemotherapy is given before radical surgery to reduce the bulk of the tumor",
      "Chemotherapy is given after radical surgery for micrometastases",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Chemotherapy given BEFORE surgery to reduce tumor bulk (Option C)**\n\nüî¨ **NEOADJUVANT CHEMOTHERAPY:**\n\n**DEFINITION:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Chemotherapy BEFORE** definitive treatment (surgery/RT) ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Goal:** Downstage tumor, improve resectability\n\n**ADVANTAGES:**\n‚Ä¢ **Shrinks tumor** ‚Üí easier resection ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Tests chemo-sensitivity** in vivo\n‚Ä¢ **Treats micrometastases** early\n‚Ä¢ **Better organ preservation**\n\n**INDICATIONS:**\n‚Ä¢ **Locally advanced tumors** ‚≠ê\n‚Ä¢ **Cervical cancer** (Stage IB2-IIA)\n‚Ä¢ **Breast cancer** (locally advanced)\n‚Ä¢ **Bladder cancer**\n‚Ä¢ **Rectal cancer**\n\n**VS ADJUVANT:**\n‚Ä¢ **Adjuvant:** Chemotherapy AFTER surgery ‚≠ê\n‚Ä¢ **Goal:** Treat micrometastases\n\n**VS CONCURRENT:**\n‚Ä¢ **Concurrent:** Chemo WITH radiation (radiosensitizer)\n\n**THIS CASE:**\n‚Ä¢ **Stage IIA cervical cancer**\n‚Ä¢ **Neoadjuvant** ‚Üí shrink ‚Üí **radical hysterectomy**\n\nüí° **KEY:** **Neoadjuvant = BEFORE surgery (to downstage)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-162",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A patient presents with sudden onset of hematemesis. He has been taking aspirin for his arthritis and drinks alcohol occasionally. He gives a history of occasional abdominal pain. On examination, there is no abdominal mass or tenderness. What is the likely diagnosis?",
    options: [
      "Mallory-Weiss tear",
      "Esophagitis",
      "Peptic ulcer r",
      "Esophageal varices",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Peptic ulcer (Option C)**\n\nüî¨ **PEPTIC ULCER DISEASE (PUD) - ACUTE BLEEDING:**\n\n**THIS CASE:**\n‚Ä¢ **Sudden hematemesis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Aspirin use** ‚≠ê‚≠ê‚≠ê (NSAID)\n‚Ä¢ **Alcohol** ‚≠ê\n‚Ä¢ **Occasional abdominal pain** ‚≠ê (ulcer symptoms)\n‚Ä¢ **No mass/tenderness** (NO peritonitis)\n\n**PEPTIC ULCER:** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Most common cause** of upper GI bleeding ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Risk factors:** NSAIDs ‚≠ê, H. pylori, alcohol\n\n**ASPIRIN & PUD:**\n‚Ä¢ **Inhibits COX-1** ‚Üí ‚Üì prostaglandins\n‚Ä¢ **Loss of mucosal protection** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bleeding risk** increased\n\n**WHY NOT OTHERS:**\n\n‚Ä¢ **Mallory-Weiss:** Post-vomiting tear (NO prior vomiting here)\n‚Ä¢ **Esophagitis:** Heartburn, dysphagia (NO massive bleeding)\n‚Ä¢ **Varices:** Chronic liver disease, cirrhosis (NOT mentioned)\n\n**MANAGEMENT:**\n‚Ä¢ **Resuscitation** (IV fluids, blood)\n‚Ä¢ **PPI** (high-dose)\n‚Ä¢ **Endoscopy** (diagnosis + hemostasis)\n\nüí° **KEY:** **Aspirin + Hematemesis + Abdominal pain = Peptic ulcer bleeding** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-164",
    subjectId: "surgery",
    chapterId: "neet-pg-2023",
    question: "A 40-year-old male patient presents with a swelling that has been slowly growing in the past 2 years. On examination, it was variable in consistency and fully mobile. What is the most likely diagnosis?",
    options: [
      "Dermoid cyst d",
      "Parotid tumor d",
      "Sebaceous cyst a",
      "Cervical lymph node",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Parotid tumor (Option B)**\n\nüî¨ **PAROTID GLAND TUMOR:**\n\n**THIS CASE:**\n‚Ä¢ **Slow-growing swelling** (2 years) ‚≠ê\n‚Ä¢ **Variable consistency** ‚≠ê‚≠ê‚≠ê **(CHARACTERISTIC)**\n‚Ä¢ **Fully mobile** ‚≠ê\n‚Ä¢ **Location:** Parotid region (from image)\n\n**VARIABLE CONSISTENCY = PATHOGNOMONIC** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Pleomorphic adenoma** (benign mixed tumor) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Most common parotid tumor** (80% of parotid tumors)\n‚Ä¢ **Contains both epithelial & mesenchymal elements**\n\n**PLEOMORPHIC ADENOMA:**\n‚Ä¢ **Slow growth** ‚≠ê\n‚Ä¢ **Painless**\n‚Ä¢ **Mobile** (not fixed)\n‚Ä¢ **Variable/Lobulated** surface\n‚Ä¢ **Facial nerve intact** (no palsy)\n\n**DIAGNOSIS:**\n‚Ä¢ **FNAC** (Fine needle aspiration)\n‚Ä¢ **MRI** (extent, facial nerve relation)\n\n**TREATMENT:**\n‚Ä¢ **Superficial parotidectomy** with **facial nerve preservation** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Risk:** Facial nerve injury, Frey's syndrome\n\n**MALIGNANT FEATURES:**\n‚Ä¢ **Rapid growth**, **Pain**, **Facial palsy**, **Fixed**\n\nüí° **KEY:** **Slow parotid swelling + Variable consistency = Pleomorphic adenoma** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page81_img42.jpeg",
    year: 2023
  }
];

export default questions;

// Helper function to get questions by chapter
export function getQuestionsByChapter(chapterId: string): Question[] {
  return questions.filter(q => q.chapterId === chapterId);
}

// Export question count
export const questionCount = questions.length;
